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1 Abbreviations 
A Ampere 
AM Acetoxymethylester 
AnxV Annexin V 
APC Allophycocyanin or antigen-presenting cell 
APC-Cy7 Allophycocyanin-cyanine 7 
APS Ammonium persulfate 
Arm Ham Armenian hamster 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
BRCA1 Breast cancer 1 
BSA Bovine serum albumin 
BUV395 BD Horizon Brilliant™ Ultraviolet 395 
C12-FDG 5-dodecanoylaminofluorescein-di-β-D-galactopyranoside 
CD Cluster of differentiation 
CFSE Carboxyfluorescein succinimidyl ester 
cGAMP Cyclic guanosine monophosphate-adenosine monophosphate 
cGas Cyclic GMP-AMP synthase 
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T-lymphocyte-associated protein-4 
δ-ALAS δ-aminolevulinic acid synthase 
Da Dalton 
DAMP Damage-associated molecular pattern 
ddH2O Double distilled water 
dNTP Deoxynucleoside triphosphate 
EDTA Ethylenediaminetetraacetic acid 
e.g. For example 
EGF Epidermal growth factor 
Egr-1 Early growth response protein 1 
EGTA Ethyleneglycoltetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ER Estrogen receptor α 
ESL1 E-selectin ligand 1 
T:E Target to effector ratio 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
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FSC Forward scatter 
g Gram or gravitational acceleration 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
Gy Gray 
h Hour 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Her2/neu Human epidermal growth factor receptor 2 
HRP Horse radish peroxidase 
HSP Heat shock protein 
HUVEC Human umbilical vein endothelial cell 
ICAM-1/-2 Intercellular adhesion molecule 1/2 
i.e. That is 
IFN Interferon 
IGEPAL CA-630 Octylphenoxypolyethoxyethanol 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IL Interleukin 
IORT Intraoperative radiotherapy 
IRF3 Interferon regulatory factor 3 
l Liter 
k Kilo (103) 
LFA-1 Lymphocyte function-associated antigen 1 
LPS Lipopolysaccharides 
m Milli (10-3) or meter 
µ Micro (10-6) 
M Molar (mol/l) 
Mac-1 Macrophage receptor 1 
MCP Monocyte chemotactic protein 
MDSC Myeloid-derived suppressor cell 
MHC Major histocompatibility complex 
MIF Macrophage migration inhibitory factor 
min Minute 
MOMP Mitochondrial outer membrane potential 
Mw Molecular weight 
n Nano (10-9) 
n.d. Not detected 
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NKC Natural killer cell 
Nlrp3 NOD-like receptor family pyrin domain containing-3 protein 
NOD-like Nucleotide-binding oligomerization domain-like 
p Piko (10-12) 
PAMP Pathogen-associated molecular pattern 
PARP Poly(ADP-ribose)polymerase 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PD1 Programmed cell death receptor 1 
PDL-1 Programmed death ligand 1 
PE Phycoerythrin 
PECAM-1 Platelet endothelial cell adhesion molecule 1 
PE-Cy5/7 Phycoerythrin-cyanine 5/7 
PerCP-Cy5.5 Peridinin-chlorophyll-cyanine 5.5 
PI Propidium iodide 
PP Polypropylene 
PR Progesterone receptor 
PRR Pattern recognition receptor 
PS Phosphatidylserine 
PSGL1 P-selectin glycoprotein ligand 1 
PVDF Polyvinylidene difluoride 
RAGE Receptor for advanced glycation endproducts 
RIPK1 Receptor-interacting protein kinase 1 
rpm Rotations per minute 
s Second 
SA-β-gal Senescence-associated β-galactosidase 
SASP Senescence-associated secretory phenotype 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SSC Sideward scatter 
SDF-1α Stromal cell-derived factor 1α 
STING Stimulator of interferon genes 
TAM Tumor-associated macrophage 
TBS Tris-buffered saline 
TEMED Tetramethylethylenediamine 
TGF-β Transforming growth factor β 
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TLR Toll-like receptor 
TNF Tumor necrosis factor 
U Unit 
UTP Uridine triphosphate 
V Volt 
VCAM-1 Vascular cell adhesion molecule 1 
VLA-4 Very late antigen 4 
vs. versus 
yFMI Forward migration index in y-direction 
zVAD-fmk Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone 
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2 Zusammenfassung 
Neben Chirurgie und Chemotherapie ist die Strahlentherapie ein zentraler 
Bestandteil bei der Behandlung von Brustkrebs. Brustkrebs-Patientinnen werden 
klassischer Weise adjuvant fraktioniert bestrahlt, d.h. mit täglichen Dosen zwischen 
1,8 und 2 Gy bis zu einer Gesamtdosis von 50-60 Gy nach brusterhaltender 
Operation. Aktuell sind hypofraktionierte Schemata mit täglich 2,66 Gy und mehr auf 
dem Vormarsch und in einigen Ländern bereits Standard. Zusätzlich zur 
fraktionierten Bestrahlung werden auch ablative Ansätze, z.B. in Form einer intra-
operativen Bestrahlung (IORT), angeboten. Hierbei wird direkt nach der 
chirurgischen Resektion eine hohe Einzeldosis von bis zu 20 Gy in das ehemalige 
Tumorbett appliziert. Die Wirkung der Strahlentherapie beruht im Wesentlichen auf 
der Induktion von Tumorzelltod durch irreparable Schädigung der DNA. Es gibt 
jedoch zunehmend Hinweise für einen relevanten Beitrag des Immunsystems zum 
strahlentherapeutischen Erfolg. In verschiedenen Mausmodellen konnte gezeigt 
werden, dass vor allem ablative Bestrahlungsschemata in der Lage sind, adaptive 
Immunmechanismen nicht nur gegen den lokal bestrahlten Tumor, sondern auch 
gegen Fernmetastasen außerhalb des Bestrahlungsfeldes (sog. abskopale Effekte), 
auszulösen. Die genauen Mechanismen, die diesen immunologischen Vorgängen zu 
Grunde liegen, sind nur rudimentär verstanden. Vor allem die Eigenheiten 
verschiedener Bestrahlungsschemata im Hinblick auf die Induktion systemischer 
Anti-Tumor-Immunantworten konnten bisher nur unvollständig geklärt werden. 
Allerdings scheint die durch die unterschiedlichen Bestrahlungsregime 
hervorgerufene Art des Tumorzelltods eine entscheidende Rolle zu spielen. Um 
diese Hypothese zu überprüfen, wurden in der vorliegenden Dissertation 
verschiedene Brustkrebszelllinien verschiedenen Bestrahlungsschemata unterzogen 
und die daraus resultierenden immunologischen Effekte untersucht. Es konnte 
gezeigt werden, dass ablative Bestrahlung besser als jedes andere der getesteten 
Regimes sehr stark primäre Nekrose auslöst, insbesondere in schnell 
proliferierenden, tripel-negativen Brustkrebs-Zelllinien. Diese nekrotischen 
Brustkrebszellen setzen in der Folge Attraktionssignale frei, die in vitro Transwell-
Migration und ungerichtete Chemokinese von Monozyten stimulierten. In vivo wurde 
die ungerichtete Chemokinese in gerichtete Leukozyten-Rekrutierung umgewandelt. 
Zentrale Vermittler in diesem Zusammenhang scheinen Endothelzellen zu sein, die 
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nach Exposition mit Überständen bestrahlter Brustkrebszellen stark aktiviert wurden. 
Die Endothelzell-Aktivierung war gekennzeichnet durch eine gesteigerte Expression 
von Adhäsionsmolekülen auf der Endotheloberfläche sowie durch die Freisetzung 
von Zytokinen und Chemokinen. Bemerkenswerterweise war das Endothelzell-
mRNA-Profil von Adhäsionsmolekülen und pro-inflammatorischen Zytokinen nach 
Inkubation mit Überständen ablativ bestrahlter Brustkrebszellen einzigartig und 
unterschied sich klar von den Profilen, die mit anderen Bestrahlungsschemata 
beobachtet wurden. Für die beschriebenen Effekte auf Endothelzellen waren 
proteinartige Gefahrensignale (DAMPs) von sterbenden Brustkrebszellen 
verantwortlich. Des Weiteren waren diese Protein-DAMPs dafür verantwortlich, dass 
die Differenzierung und Maturierung Antigen-präsentierender Zellen aus 
Peripherblut-Monozyten verbessert wurde, was sich durch eine verstärkte Expression 
ko-stimulatorischer Moleküle auf ihrer Oberfläche darstellte. Diese dendritischen 
Zellen waren dadurch signifikant besser in der Lage, die Proliferation von CD8+ T-
Zellen zu stimulieren. Die beschriebenen immunologischen Vorgänge zeigten ein 
einheitlich wiederkehrendes Schema: Die stärksten Effekte wurden beobachtet, wenn 
Überstände ablativ bestrahlter Brustkrebszellen eingesetzt wurden. Tatsächlich 
wurden auch die höchsten Konzentrationen von Protein-DAMPs in den Überständen 
der ablativ bestrahlten Brustkrebszellen gefunden. Zusammenfassend lässt sich 
festhalten, dass vor allem eine ablative Bestrahlung von Brustkrebszellen und der 
dadurch ausgelöste immunogene Zelltod das Potential haben, systemische Anti-
Tumor-Immunmechanismen auszulösen. 
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3 Abstract  
Besides surgery and chemotherapy, radiotherapy is a central component of breast 
cancer therapy. Classically, the treatment comprises an adjuvant, fractionated 
radiation regimen, i.e. patients receive daily doses of 1.8-2 Gy up to a total dose of 
50-60 Gy, after breast conserving surgery, but hypofractionated regimens of daily 
2.66 Gy or more are being on the rise. In addition to fractionated radiotherapy, 
ablative settings are also clinically available, for instance during intra-operative 
radiotherapy (IORT). Here, high single doses of up to 20 Gy are applied into the 
former tumor bed directly after surgery. The main effect of radiotherapy is the 
induction of tumor cell death as a consequence of excessive DNA damage. However, 
accumulating evidence suggests a relevant contribution of the immune system to the 
radiotherapeutic success. In different mouse models, radiotherapy was shown to 
induce adaptive anti-tumor immune mechanisms (so-called abscopal effects) not only 
against the locally irradiated tumor but also against distant out-of-field metastases – 
particularly when applied in ablative settings. The mechanisms underlying these 
immunological effects remain poorly understood, and little is known about the 
characteristics of different irradiation regimens with regard to their potential to induce 
systemic anti-tumor immunity. Nevertheless, the quality of tumor cell death induced 
by different irradiation regimens appears to be of crucial importance in this scenario. 
To evaluate this hypothesis, a panel of breast cancer cell lines was subjected to 
different irradiation regimens, and the resulting immunological effects were 
investigated. Ablative irradiation induced primary necrosis more potently than all 
other irradiation regimens tested, and this was most obvious in fast-proliferating 
breast cancer cells. Necrotically dying breast cancer cells, in turn, released attraction 
signals, which stimulated trans-well migration and undirected chemokinesis of 
monocytic cells in vitro. Importantly, this undirected chemokinesis was converted into 
directional leukocyte recruitment in vivo. Key players in this regard appear to be 
endothelial cells, which were strongly activated upon exposure to releasates of 
irradiated breast cancer cells in vitro, thus expressing high levels of adhesion 
molecules on their surface and releasing various cytokines and chemokines. Notably, 
for supernatants of ablatively irradiated breast cancer cells, the endothelial mRNA 
profile of adhesion molecules and pro-inflammatory cytokines was unique and clearly 
distinct from the ones observed with other irradiation regimens. The effects on 
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endothelial cells were exerted by proteinaceous damage-associated molecular 
patterns (DAMPs) derived from dying breast cancer cells. Furthermore, dying breast 
cancer cell-derived protein DAMPs enforced differentiation and maturation of antigen-
presenting cells from peripheral blood monocytes as characterized by elevated 
expression of co-stimulatory molecules. In consequence, the CD8+ T cell-stimulating 
capacity of these dendritic cells was significantly increased. Consistently, the 
observed immunological processes revealed a recurring pattern: The strongest 
effects were obtained with supernatants of ablatively irradiated breast cancer cells, in 
which the highest concentrations of DAMPs were found. In summary, these results 
indicate that irradiation-induced immunogenic cell death of breast cancer cells has 
the potential to provoke systemic anti-tumor immune mechanisms – especially upon 
ablative irradiation. 
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4 Introduction 
4.1 Immune-stimulatory effects of radiotherapy 
In 1953, R.H. Mole was the first describing ‘abscopal’ effects of radiotherapy 1. 
Abscopal (from Latin ‘ab’ and Greek ‘scopus’: ‘away from target’) effects are systemic 
bystander effects of local irradiation which do not only lead to regression of the 
irradiated tumor but also of distant metastases outside the radiation field. Ever since 
Mole’s observations, an emerging number of case reports were published, observing 
abscopal effects in a variety of tumor types, including lymphoma, metastatic 
melanoma, and metastatic non-small cell lung cancer 2 3 4 5.  
Seminal studies from Demaria et al. demonstrated that abscopal effects of 
radiotherapy derive from systemic anti-tumor immune responses 6. These were 
pioneering findings, since according to the concept of tumor immuno-editing, clinically 
occurring tumors are the result of a selection process of neoplastic cells that have 
escaped from immune destruction 7 (Figure 1): During cancer development, 
transformed cells are recognized, attacked, and eliminated by the host’s innate and 
adaptive immune system (elimination phase). However, ongoing pressure of the 
immune system may select tumor cells that survive the elimination phase. In the 
course of this this equilibrium phase, novel tumor cell subclones with acquired non-
immunogenic phenotypes can emerge and contribute to increased resistance to 
immune attack. Due to immune cell exhaustion, the equilibrium phase finally transits 
into the escape phase, which is characterized by accumulation of suppressive 
immune cells, such as CD4+ regulatory T cells (Tregs) and myeloid-derived suppressor 
cells (MDSCs), and the development of poorly immunogenic or even immune-
inhibitory tumor cells, for instance by upregulation of the CD8+ T cell-inhibitory ligand 
PDL-1 and downregulation of MHC class I molecules. At this stage, tumor cells have 
successfully evaded elimination by the immune system, resulting in uncontrolled 
expansion, finally manifesting in clinically detectable, progressively growing tumors. 
In order to elicit systemic anti-tumor mechanisms, escaped tumor cells need to be 
unmasked for the host’s immune system. In principle, radiotherapy appears to have 
the capacity to provoke such a change in tumor cell immunogenicity. Formenti and 
Demaria coined the concept that radiotherapy is a powerful means of in situ 
vaccination, because it reinforces the host’s immune system against local tumors as 
well as distant – i.e. abscopal – metastases 8.  
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Figure 1 The process of tumor immuno-editing is a three-step process (adapted from 7). 
Tumor immuno-editing is divided into three phases: Elimination, equilibrium, and escape. The 
transformation of normal cells into tumor cells is induced by various stimuli. These include 
carcinogens, radiation, chronic inflammation, activation of proto-oncogens, and oncoviruses. Usually, 
transformed tumor cells are recognized and rapidly eliminated by cells of the innate and adaptive 
immune system, such as macrophages, NK cells, and effector CD4+/CD8+ T cells (elimination phase). 
Incomplete elimination of tumor cells results in equilibrium, where immune cells prevent the tumor from 
further expansion but at the same time are unable to remove the tumor entirely (equilibrium phase). In 
turn, tumor cell variants with immune-evasive and immune-suppressive features emerge, and the 
constant pressure of the immune system selects these aggressive, poorly immunogenic tumor cells. 
Tumor escape mechanisms include downregulation of MHC class I molecules and upregulation of the 
T cell-inhibiting molecule PDL-1. Furthermore, immune cell exhaustion supports the transition from the 
equilibrium phase to the tumor escape phase. Here, the immune system is no longer able to control 
the tumor cell variants. Distinct immune subpopulations are polarized into tumor-supporting cells (e.g. 
myeloid-derived suppressor cells). Finally, the escape phase results in progressively growing, clinically 
manifesting tumors. CD, cluster of differentiation; IFN, interferon; NKC, natural killer cell; MHC, major 
histocompatibility complex; MDSC, myeloid-derived suppressor cell; PD1, programmed cell death 
receptor 1; PDL-1, programmed death ligand 1; Treg, regulatory T cell. 
 
Since the first publication in 2004, several groups have strived to elucidate the 
mechanisms underlying radiation-induced anti-tumor immunity. On the basis of the 
corresponding observations, a model of an irradiation-induced cascade of type I 
(IFNα/β) and type II (IFNγ) interferons with the involvement of dendritic cells and 
CD8+ T cells has been proposed (Figure 2). 
Neoplastic transformation induced by
- Carcinogens
- Radiation
- Chronic inflammation
- Inherited defects
- Viruses
.......
CD8+ T cell
CD4+ T cell
Macrophage NK cell
Tumour cell
.......CD8+ T cell NK cell
CD4+ T cell
.......
Epithelial cell
Elimination (Cancer immunosurveillance)
Equilibrium (Cancer persistence)
Genetic instability and/or immune selection
.......
.....
.. NK cell
Treg cell
MDSCCD8+ T cell
PDL-1
Escape (Cancer progression: non-immunogenic tumours)
- Immune exhaustion or inhibition
- Tumour-cell variants
MHC class 1 molecules
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Figure 2 A cascade of type I and II interferons induced by ablative irradiation contributes to 
tumor control (adapted from 9). 
In different mouse models, it was shown that ablative irradiation of tumor cells leads to production of 
type I interferons (IFNα/β) from tumor-infiltrating monocytic cells, such as dendritic cells and 
macrophages. These type I interferons enhance cross-presentation of tumor-antigens by dendritic 
cells to CD8+ T cells in the lymph nodes. Upon activation, cytotoxic CD8+ T cells (and NK cells) 
produce IFNγ, which not only promotes anti-tumor functions of immune cells but also increases the 
immunogenicity of tumor cells, and inhibits tumor growth, finally resulting in local and systemic tumor 
control. CTL, cytotoxic T lymphocyte; DC, dendritic cell; IFN, interferon; NKC, natural killer cell. 
 
In 2005, Lugade and colleagues could show that ablative radiation, i.e. one single 
dose of 15 Gy, of B16 murine melanomas induces the generation of tumor-specific, 
IFNγ-producing effector T cells and enhances their intra-tumoral accumulation 10. The 
same group described later that IFNγ produced by anti-tumor effector T cells elevates 
the immunogenicity of irradiated tumor cells by enhancing MHC class I expression on 
melanoma cells and shaping the tumor’s vasculature for leukocyte trafficking 11. 
Moreover, the important role of IFNγ not only in increasing the immunogenicity of 
tumor cells but also for CD8+ T cell effector function after ablative radiation was 
confirmed by Gerber and colleagues 12. Lee and colleagues highlighted the 
indispensability of CD8+ T cells for the control of the local tumor as well as distant, 
out-of-field (abscopal) metastases after ablative irradiation 13. Another study of 
Burnette and colleagues revealed that, besides IFNγ, type I IFNs (IFNα/β) produced 
by tumor-infiltrating dendritic cells upon ablative radiation are crucial for the induction 
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of potent anti-tumor immune responses. They could show that type I IFNs strongly 
enhance the cross-priming activity of dendritic cells and CD8+ T cells in tumor-
draining lymph nodes 14 via autocrine mechanisms 15. In accordance, Diamond et al. 
and Fuertes et al. showed that type I IFNs have functions distinct from those of IFNγ 
in anti-tumor immunity: while IFNγ mainly enhances the immunogenicity of tumor 
cells themselves, type I IFNs elevate the immune-stimulatory effects of cells of the 
innate immune system 16 17. Moreover, it was recently shown that type I IFNs also 
support the intra-tumoral recruitment of effector CD8+ T cells by inducing chemokine 
release from intra-tumoral macrophages after ablative radiotherapy 18. The 
mechanisms behind the production of type I IFNs by tumor-infiltrating dendritic cells 
upon radiation are currently still being investigated. So far, a pathway known from 
pathogen defense was brought into focus: Cytosolic sensing of tumor DNA by 
dendritic cells can lead to the production of cyclic guanosine monophosphate-
adenosine monophosphate (cGAMP) by cyclic GMP-AMP synthase (cGAS). cGAMP 
acts as a second messenger, thereby activating the adaptor protein stimulator of 
interferon genes (STING), which in turn enables the production of type I IFNs by the 
transcription factor interferon regulatory factor 3 (IRF3) 19 20. Interestingly, in the 
context of anti-viral immunity, Ablasser and colleagues could show that cGAMP-
producing cells are able to transfer cGAMP to neighboring cells, which activates 
STING-dependent production of type I IFNs, thus inducing ‘bystander immunity’ 21. 
It should be noted that irradiation-induced anti-tumor immune responses seem to rely 
predominantly on dendritic cells and CD8+ T cells, while CD4+ T cells (and 
macrophages) appear to be dispensable – at least in certain settings 22. However, the 
role of CD4+ T cells in anti-tumor immunity is dependent on the CD4+ T cell subset: 
CD4+ helper 1 T cells (Th1) can augment the generation of anti-tumor CD8+ T cells 
after radiotherapy, and the ablation of intra-tumoral immune-suppressive CD4+ Tregs 
greatly enhances the immunogenicity of established tumors and improves the 
outcome of radiotherapy 14 23 24. Furthermore, Filatenkov and colleagues showed that 
IFNγ-producing CD8+ T cells generated upon ablative irradiation do not only eliminate 
tumor cells but also intra-tumoral suppressor cells (e.g. MDSCs), thereby shifting the 
immune-suppressive tumor microenvironment into an immune-supportive one 25. 
In addition, radiotherapy itself improves the immunogenicity of tumor cells, e.g. it 
increases MHC class I surface expression 26 and induces Fas-receptor upregulation 
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27 on tumor cells, thus improving their recognition and elimination by cytotoxic CD8+ T 
cells. 
Notably, most studies describing induction of anti-tumor immunity by radiotherapy 
were performed using ablative settings, i.e. single doses of 10 Gy and more. 
However, in clinical practice, the application of ablative irradiation is limited to 
accessible, small tumor volumes, whereas fractionated irradiation regimens, i.e. daily 
doses of approximately 2 Gy over several weeks, are most commonly applied 28 29 30. 
Induction of anti-tumor immunity, as described above, is rarely seen when using 
fractionated radiation regimens 13 25. Only extremely hypofractionated settings, i.e. 
doses of 7.5 Gy in two fractions were also able to induce anti-tumor immunity 31. The 
mechanisms behind the differences between ablative and fractionated irradiation in 
inducing adaptive anti-tumor immunity are poorly understood. A relevant cancer 
entity to investigate these mechanisms is breast cancer, because here fractionated, 
hypofractionated, and ablative regimens are used in parallel without hard-wired 
stratification markers at hand. Moreover, the infiltration of CD8+ T cells was shown to 
be predictive for the clinical outcome in breast cancer 32, emphasizing the clinical 
relevance of immunological studies in the context of breast cancer radiotherapy. 
4.2 Epidemiology and treatment of breast cancer 
Breast cancer is the most frequent cancer entity in women with about 70,000 new 
cases per year in Germany (according to the Robert Koch-Institute, see 
www.krebsdaten.de). These tumors commonly develop from transformed cells of the 
milk ducts and lobules. In most cases, breast cancers are reliant on the female 
sexual hormones estrogen and progesterone, and/or on epidermal growth factor 
(EGF). The overexpression of the corresponding receptors defines the therapeutic 
treatment regimen and is of prognostic value. Stratification is based on 
histopathological examination of estrogen-receptor α (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (Her2/neu). Since ER and PR 
are steroid hormone receptors, they are mainly found in the cytosol. Upon ligand 
binding, they translocate into the nucleus, where they act as transcription factors. In 
contrast, Her2/neu is a plasma membrane-bound receptor tyrosine kinase which 
activates downstream pathways by phosphorylation of adaptor proteins upon ligation. 
Treatment of ER-positive breast cancer is based on the neutralization of the 
activating ligand estrogen. This can be achieved either by inhibiting ER with small 
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molecules, such as tamoxifen or raloxifen, or by inhibiting the synthesis of estrogens. 
Aromatase inhibitors, such as anastrozol, block a key enzyme in the estrogen 
synthesis pathway, thereby decreasing endogenous estrogen levels. Breast cancer 
cells overexpressing Her2/neu are commonly treated with the monoclonal antibody 
trastuzumab, blocking Her2/neu itself 33. However, no specific therapy is available for 
breast cancers overexpressing neither hormone receptors nor Her2/neu. These so 
called triple-negative breast cancers are the most malignant subtype 34. They 
develop particularly in younger women (<40 years) and are associated with 
specifically poor prognosis in comparison to other breast cancer subtypes 35. In 
addition to classical histopathological stratification, molecular subtypes of breast 
cancer were defined on the basis of gene expression patterns 36 37. Although no 
generally accepted classification has been proposed yet, three molecular subtypes 
seem to be of importance: The luminal, the basal, and the Her2-enriched subtype. 
The luminal molecular subtype occurs mainly as ER-overexpressing breast cancer, 
while the basal and the Her2/neu subtype mainly reflect triple-negative or Her2/neu-
overexpressing breast cancers, respectively 38. 
Mutations in several genes of the DNA damage response involved in DNA repair are 
clearly linked to the development of breast cancer. For instance, women carrying 
mutations in one allele of the Breast cancer 1 (BRCA1) gene have a 60% risk to 
develop breast cancer by the age of 70 39 40. The risk for ovarian cancer is also 
elevated for BRCA1 mutation carriers. Of note, BRCA1 mutations are inherited. 
Besides BRCA1, other genes have been identified as potential breast cancer driving 
genes. These include BRCA2, PALB2, ATM, and PTEN 41. Interestingly, the mutation 
status of the well-known tumor suppressor p53 differs between the breast cancer 
subtypes: Mutations of p53 are found less often in ER overexpressing breast cancers 
than in triple-negative breast cancers 38. Mechanistically, this might be explained by 
the observation that in ER-overexpressing breast cancer ER is able to bind p53, thus 
abrogating its tumor suppressing functions 42 43. 
Standard treatment of breast cancer includes fractionated radiotherapy in an 
adjuvant setting i.e. after breast conserving surgery. Patients receive daily fractions 
of 1.8 – 2 Gy over several weeks up to a total dose of about 50-60 Gy. The benefits 
of fractionated radiotherapy on tumor burden and tolerability are well described in the 
literature 44: Fractionated radiotherapy leads to tumor cell elimination with concurrent 
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reduced normal tissue reactions, since tumor cells and normal tissue differ with 
regard to their DNA damage repair efficiency: Normal tissue cells can repair DNA 
damage between the fractions due to functional DNA repair mechanisms, while most 
tumor cells show deficiencies in DNA repair. Furthermore, tumor reoxygenation and 
redistribution of tumor cells into more radiosensitive phases of the cell cycle can 
occur between the fractions. Hypofractionated regimes with less but higher daily 
doses currently find their way into the clinical routine. Especially in Canada and the 
UK, hypofractionation with 2.66 Gy per day and shortened overall treatment time is 
already standard, and ongoing trials will elucidate whether even higher single doses 
(5.7-6 Gy) may define a new optimum 45. In addition, ablative irradiation using 
intraoperative radiotherapy (IORT) is clinically available. In IORT, single high doses 
of up to 20 Gy are applied into the former tumor bed directly after tumor resection 46. 
Notably, the 5-year local recurrence as well as breast cancer mortality of IORT-
treated patients is similar to those treated with classically fractionated regimens 47. 
4.3 Triggering adaptive anti-tumor immunity by radiotherapy 
Figure 3 summarizes the essential steps for the induction of adaptive anti-tumor 
immunity by radiotherapy, which will be outlined in the following sections. 
4.3.1 DAMP release is a hallmark of immunogenic cell death and can be induced by 
ionizing irradiation 
Induction of immunogenic cancer cell death has been reported as a powerful first 
step for the stimulation of systemic anti-tumor immunity 49 (Figure 3). It is 
characterized by release of DAMPs 50. DAMPs are evolutionarily conserved 
intracellular molecules, which have distinct roles within the cell under normal 
conditions. Upon release into the extracellular space, these molecules exert 
important pro-inflammatory functions. Cells of the innate immune system recognize 
DAMPs via pattern recognition receptors (PRRs), including toll-like receptors (TLRs), 
C-type lectin receptors, nucleotide-binding oligomerization domain-like receptors 
(NOD-like receptors), retinoic acid-inducible gene I-like receptors (RIG-I-like 
receptors), and others. Upon receptor binding, DAMPs modulate multiple functions of 
the cell. For example, they stimulate dendritic cell maturation by upregulation of MHC 
molecules and co-stimulatory receptors and induce lymph node homing of dendritic 
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cells, resulting in enhanced (cross-) priming of naïve T cells 26. Beside others, 
nucleotides, HSP70, HMGB1, and S100 proteins are well-known DAMPs. 
 
Figure 3 The concept of irradiation-induced anti-tumor immunity (adapted from 48). 
Ionizing irradiation can induce immunogenic forms of tumor cell death, which are characterized by 
release of DAMPs. These DAMPs activate endothelial cells resulting in recruitment and extravasation 
of monocytic cells to sites of tumor cell death. Monocytes differentiate into dendritic cells and 
macrophages, engulf dying tumor cell-derived material and mature. Mature dendritic cells leave the 
tumor and enter the draining lymph nodes. There, they cross-present tumor antigens to naïve CD8+ T 
cells, which proliferate and differentiate into cytotoxic T cells upon stimulation. Cytotoxic T cells leave 
the lymph nodes and eliminate not only primary tumor cells but also distant metastases outside the 
irradiation field (abscopal effects) upon recognition of their cognate tumor antigen. CD, cluster of 
differentiation; DC, dendritic cell; DAMP, damage-associated molecular pattern. 
 
Nucleotides, such as adenosine triphosphate (ATP) and uridine triphosphate (UTP), 
exert at least two different immune functions, depending on the type of purinergic 
receptor they are interacting with: Binding to the purinergic receptor P2RX7 leads to 
activation of the NOD-like receptor family pyrin domain containing-3 protein (Nlrp3) 
inflammasome of dendritic cells and tissue-resident monocytes, resulting in 
production and secretion of pro-inflammatory interleukin (IL)-1β 51 52 53. Additionally, 
ATP and UTP were identified as attraction signals for P2RY2-expressing cells 54. 
Therefore, nucleotides can also act as ‘find-me’ signals of dying cells for phagocytes. 
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However, instead of directly stimulating chemotaxis in target cells, ATP and UTP 
rather function as autocrine amplifiers of monocyte chemotaxis and paracrine 
stimulators of cytokine and chemokine production in monocytes and endothelial cells 
52 55. ATP can either be actively secreted during apoptosis via a caspase-3 
dependent opening of pannexin1 channels or passively released during necrosis 56.  
As mentioned before, not only nucleotides but also intracellular proteins are well-
known DAMPs. One of those is the chaperone HSP70. Since tumor cells are highly 
dependent on the stabilization and overexpression of oncogenic proteins, the basal 
expression levels of chaperones, such as HSP70 and HSP90, are higher than in non-
malignant cells. HSP70 is a stress-inducible protein, which can be released in 
response to ionizing irradiation, especially in combination with hyperthermia 57. 
Released HSP70 stimulates the upregulation of the co-stimulatory molecule CD80 as 
well as the lymph node homing receptor CCR7 on dendritic cells. Furthermore, 
membrane-bound HSP70 on tumor cells was shown to support natural killer cell 
(NKC)-dependent tumor elimination 58 59. 
Another well-known DAMP is High mobility group box protein 1 (HMGB1). Under 
physiological conditions, HMGB1 is bound to DNA in the nucleus. During necrosis, it 
is passively released and acts as a highly immunogenic signal 60 61, especially for 
dendritic cells: It activates TLR4 leading to enhanced cross-presentation of tumor 
antigens to CD8+ T cells 62. Interestingly, the immunogenic potential of HMGB1 is 
dependent on its oxidation status: Completely reduced HMGB1 promotes leukocyte 
recruitment, while disulfide-HMGB1 is highly pro-inflammatory In contrast, oxidized 
HMGB1 is important for the resolution of inflammation 63. Apart from TLR4, HMGB1 
also interacts with other PRRs, such as TLR2 and RAGE 64 65. 
S100 proteins also play important roles as DAMPs. More than 20 members of the 
S100 family have been identified so far 66. They comprise a family of calcium sensing 
proteins which regulate intracellular calcium-dependent pathways 67. Many cancer 
types, such as breast cancer, melanoma, and colorectal cancer, show 
overexpression of S100 proteins 66. Particularly the S100A8/A9 heterodimer is of 
interest in the context of immune-activating signals. S100A8/A9 was shown to bind to 
TLR4 and the receptor for advanced glycation endproducts (RAGE), thereby 
stimulating the release of pro-inflammatory cytokines from monocytic cells and 
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favoring the extravasation of monocytes and neutrophils by upregulation of the 
integrin Mac-1 68 69 70 71.  
The main source of DAMPs are necrotic cells (primary and secondary necrotic ones), 
whose disintegrated plasma membrane allows passive release of intracellular 
material. Primary necrosis is referred to as an uncontrolled, accidental form of cell 
death, which is induced by extreme cell stress, for instance upon high doses of 
ionizing irradiation 72. 
 
Figure 4 Irradiation-induced cell death modalities (adapted from 9). 
Excessive irradiation-induced DNA damage which cannot be repaired, leads to various cell death 
modalities in tumor cells. Which type of cell death mode is executed, depends on multiple factors, 
such as the tumor cell’s origin, its genetic repertoire, the radiation dose, and the functionality of cell 
cycle checkpoints. Cells of the hematopoietic system primarily undergo apoptosis via the intrinsic 
(mitochondrial) pathway in response to ionizing radiation. Apoptosis is a strictly controlled mode of cell 
death. A key feature of apoptosis is the maintenance of plasma membrane integrity. If not removed in 
time by amateur or professional phagocytes, apoptotic cells can transit into secondary necrosis. In 
contrast, primary necrosis is an uncontrolled, accidental type of cell death, which is characterized by 
early loss of cell integrity and subsequent release of intracellular contents. Necroptosis is a controlled 
form of necrosis, which is regulated by RIPK1 and -3. Cells of epithelial origin mainly undergo mitotic 
catastrophe in response to ionizing radiation, when cell cycle checkpoints are defective. After several 
aberrant cell divisions, these cells commonly undergo a very chaotic, mainly necrotic form of cell 
death. However, also apoptotic phenotypes have been observed upon mitotic catastrophy. If cell cycle 
checkpoint functionality is preserved, cells may become senescent after radiation. They irreversibly 
exit the cell cycle, but remain metabolically active. MOMP, mitochondrial outer membrane potential; 
PARP, poly(ADP-ribose)polymerase; RIP, receptor-interacting protein kinase. 
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In addition to primary necrosis, irreparable DNA damage induced by irradiation leads 
to apoptosis, mitotic catastrophe, or senescence, respectively, depending on the 
cell's origin, its genetic repertoire, and the functionality of cell cycle checkpoints 
(Figure 4). Notably, these modes of cell death clearly differ in their immunogenic 
potential. In contrast to necrosis, apoptosis is a highly organized form of cell death. 
Cells of the hematopoietic system mainly undergo apoptosis in response to ionizing 
radiation via the intrinsic apoptotic pathway 73. During intrinsic apoptosis, breakdown 
of the mitochondrial outer membrane potential is followed by release of pro-apoptotic 
factors, such as cytochrome c, which leads to activation of pro-caspase-9, in turn 
activating downstream effector caspases 74. Apoptotic cells are characterized by 
membrane blebbing, chromatin condensation and DNA fragmentation. During this 
strictly controlled process of cell death, the membrane integrity stays intact. As such, 
apoptosis is an immunogenically silent form of cell death, which induces the 
production of anti-inflammatory cytokines, including transforming growth factor β 
(TGF-β) and IL-10, by phagocytes 75. However, apoptotic cells which are not 
removed in time by neighboring cells or professional phagocytes, might transit into 
secondary necrosis, thereby losing plasma membrane integrity and releasing their 
intracellular contents 76. 
Cells of epithelial origin, as is the case for most solid cancers, rarely undergo 
apoptosis in response to ionizing irradiation. If cell cycle checkpoint functions are lost, 
these cells experience mitotic catastrophe as characterized by several aberrant cell 
divisions, resulting in giant cells with abnormal nuclear morphology, which finally die 
in a highly chaotic, necrotic way. 
If cell cycle checkpoint function is still preserved, cells with excessive DNA damage 
can irreversibly exit the cell cycle and undergo cellular senescence. This is 
hallmarked by an upregulation of cyclin-dependent kinase inhibitors, such as p21, 
p27, and p16. Furthermore, activity of senescence-associated β-galactosidase is 
upregulated and commonly used for the detection of senescence 77. Senescent cells 
remain metabolically active and secrete various factors, such as chemokines, growth 
factors, and proteases. As a whole, these factors represent the senescence-
associated secretory phenotype (SASP) 78. On the one hand, DNA damage-induced 
senescence by irradiation can result in permanent and irreversible growth arrest of 
tumor cells, thus inhibiting tumor progression. On the other hand, Angelini and 
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colleagues showed that the SASP can promote breast cancer metastasis 79. To add 
complexity, Pribluda et al. described a p53-dependent mechanism, which switches 
the senescent environment from a cancer-suppressive to a cancer-promoting one 80. 
Since DAMP release by dying tumor cells is a prerequisite to alert the immune 
system, the induction of immunogenic cell death can be an essential step at the very 
beginning of the anti-tumor immune response. In contrast, large numbers of tumor 
cells undergoing non-immunogenic forms of tumor cell death might attenuate or even 
prevent effective immune reactions against cancer cells. 
Importantly, the mere existence of a pro-inflammatory milieu inside the tumor is not 
sufficient to induce potent anti-tumor immunity: The factors released from 
immunogenically dying cells must also be converted and amplified in order to attract 
immune cells to sites of tumor cell death and danger (Figure 3). This process – the 
leukocyte recruitment cascade – has been studied extensively as discussed in the 
following section. 
4.3.2 Leukocyte recruitment to sites of danger and cell death 
As one of the first steps in the induction of adaptive anti-tumor immune responses 
after irradiation, monocytes are recruited to sites of tumor cell death, were they 
subsequently differentiate into dendritic cells, which take up tumor material and  
(cross-) present it to naïve T cells in the draining lymph nodes (Figure 3).  
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Figure 5 The leukocyte adhesion cascade (adapted from 81). 
Leukocytes extravasate from the blood to sites of infection or damage. They are captured by activated 
endothelial cells and roll on their luminal surface. Both steps are mediated by the interaction between 
E- and P-selectins expressed on activated endothelial cells and their corresponding receptors on 
leukocytes (e.g. PSGL1). Subsequently, leukocytes are activated by chemokines released from 
endothelial cells, followed by arrest, spreading, and intravascular crawling. These steps are dependent 
on the interaction between integrins (e.g. LFA-1, Mac-1) expressed on leukocytes and adhesion 
molecules (e.g. ICAM-1, VCAM-1) on the surface of activated endothelial cells. Finally, leukocytes 
extravasate through the endothelial cell layer into the tissue via para- or transcellular mechanisms in a 
PECAM-1-dependent manner. ICAM-1, Intercellular adhesion molecule 1; LFA-1, Lymphocyte 
function-associated antigen 1; Mac-1, Macrophage receptor 1; PECAM-1, Platelet endothelial cell 
adhesion molecule 1;  PSGL1, P-selectin glycoprotein ligand 1; VCAM-1, vascular cell adhesion 
molecule 1. 
 
The leukocyte adhesion cascade summarizes the steps necessary for leukocyte 
recruitment from the blood stream to sites of infection and/or tissue damage (Figure 
5). This extravasation process into the tissue is typically observed in postcapillary 
venules. It is initiated by the capture or tethering of leukocytes from the blood stream 
to the surface of endothelial cells and subsequent rolling of leukocytes on the 
endothelium. Both processes are dependent on selectins 82 of which three types 
have been described: L-selectin, E-selectin, and P-selectin. The latter two are mainly 
expressed on endothelial cells and are strongly upregulated by inflammatory signals: 
DAMPs and pro-inflammatory cytokines, induce the synthesis and surface expression 
of E-selectin as well as the translocation of P-selectin, which is stored in Weibel-
Palade bodies, to the luminal side of endothelial cells. In contrast, L-selectin is not 
expressed on the endothelium but on leukocytes. All three selectins bind to P-selectin 
glycoprotein ligand 1 (PSGL1) expressed by all leukocytes. E-selectin additionally 
binds to CD44 and E-selectin ligand 1 (ESL1) 83. Temporal, reversible interaction of 
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E- and P-selectin on the activated endothelium with their cognate leukocyte ligands 
leads to capture and rolling of leukocytes on the endothelium. Recently, Zuchtriegel 
and colleagues demonstrated that rolling of neutrophils is predominantly mediated by 
P- and L-selectin interacting with PSGL1 and CD44, while inflammatory monocytes 
additionally require E-selectin 84. 
Upon rolling, leukocytes are activated and arrest on the endothelium. This is 
triggered by endothelial cell-derived chemokines and depends on the interaction 
between leukocyte integrins and adhesion molecules of the immunoglobulin 
superfamily on the activated endothelium 85. The most important integrins found on 
myeloid cells are the β2-integrins lymphocyte function-associated antigen (LFA-1; 
CD11a/CD18), macrophage receptor 1 (Mac-1; CD11b/CD18), and the β1-integrin 
very late antigen 4 (VLA-4; CD49d/CD29). Monocytes express β2- as well as β1-
integrins, whereas neutrophils express mainly β2-integrins 86. The integrin-interacting 
adhesion molecules of activated endothelial cells include ICAM-1, ICAM-2 and 
VCAM-1. Whereas β2-integrins LFA-1 and Mac-1 bind to ICAM-1 and ICAM-2, the β1-
integrin VLA-4 binds to VCAM-1 87 88. Integrins occur in three different conformations, 
which display different affinities to their corresponding ligands 89 90. However, the 
integrin activation pathways are very complex and have been reviewed elsewhere 81.  
Leukocyte arrest is followed by spreading and crawling on the endothelium. Crawling 
is also integrin-mediated, and the interaction between Mac-1 and ICAM-1/-2 is of 
crucial importance 91 92 93. The last step in leukocyte recruitment is the extravasation 
through the endothelial wall into the tissue. In principle, two ways have been 
described: The paracellular and the transcellular migration route. Both are fine-tuned 
processes, which depend on many interactions between the extravasating leukocyte 
and the endothelial cell 94. Notably, platelet endothelial cell adhesion molecule 1 
(PECAM-1; CD31), which is part of the inter-endothelial cell junctions, appears to 
play a central role in both transmigration pathways 95 96. Once the leukocyte has 
extravasated, it is guided to the site of infection or damage. In this context, pericytes 
have been shown to promote neutrophil migration after extravasation by acting as 
‘speedways’ to sites of sterile inflammation 97. 
Apart from cell adhesion molecules, recruitment of leukocytes into inflamed tissue 
requires chemokines. Several chemokines released by activated endothelial cells or 
immobilized on their surface, have been identified as potent inducers of chemotaxis 
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(i.e. directional migration towards the chemokine gradient). Based on the localization 
of cystein residues in their secondary structure, they are categorized into four main 
classes, containing the C, the CC, the CXC, or the CX3C motif, respectively. CXC 
chemokines, such as IL-8, CXCL1, and MIP-2a, are described as preferential 
chemotactic stimuli for neutrophils, while CC chemokines such as monocyte 
chemotactic protein (MCP)-1, -2, and -3 mainly attract monocytes 98 99. However, 
overlapping effects have been demonstrated 100 101. Chemokines are recognized by 
specific G-protein-coupled receptors on leukocytes guiding them along the 
concentration gradient on the endothelium. Once a leukocyte has extravasated into 
the tissue, it has to be navigated closer to the sites of danger. To this end, 
chemokine-mediated guidance as provided by endothelial cells is outcompeted by 
stronger chemotactic stimuli. For neutrophils, it was shown that dying cell-derived 
DAMPs released from mitochondria, such as formylated peptides and mitochondrial 
DNA, are hierarchically superior to endothelial chemokines, thus directing neutrophils 
to the origin of tissue damage 102 103. 
4.3.3 Dendritic cells as key players in adaptive anti-tumor immunity 
Once recruited to the site of radiation-induced tumor cell death, monocytic cells can 
differentiate into dendritic cells which are of crucial importance for the induction of T 
cell-dependent anti-tumor immunity (Figure 3). As a first step, immature dendritic 
cells derived from recruited monocytes engulf dying tumor cell material and receive 
maturation signals. The maturation process is characterized by upregulation of 
different surface molecules on dendritic cells. These include the maturation marker 
CD83 as well as the co-stimulatory molecules CD80, CD86, and CD40, as well as 
MHC class II receptors. In addition, the lymph node homing receptor CCR7 is 
upregulated on mature dendritic cells. CCR7 is essential to guide dendritic cells (as 
well as T and B cells) into the draining lymph node 104. Due to strong upregulation of 
these markers, mature dendritic cells are highly potent antigen-presenting cells 
(APCs). As mentioned in chapter 4.3.1, the maturation process of dendritic cells is 
strongly influenced by DAMPs, such as HMGB1, ATP, and HSPs 62 51 57. Mature 
dendritic cells that have captured tumor antigens enter the draining lymph nodes 
where they interact with naïve T cells. The interface between T cells and dendritic 
cells is characterized by a plethora of receptors and their corresponding ligands as 
well as various cytokines involved. Therefore, the term ‘immunological synapse’ has 
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been established 105 (Figure 6). To get into close proximity and to maintain antigen 
presentation, T cells bind ICAM-1 on dendritic cells by the integrin LFA-1 107. The 
interaction between T cells and dendritic cells is stable for several minutes 108. In 
principle, three signals are necessary for T cell stimulation by dendritic cells: (i) 
(cross-) presentation of antigens on MHC receptors to the T cell receptor, (ii) 
interaction of co-stimulatory receptors with co-stimulatory ligands, and (iii) release of 
cytokines supporting T cell differentiation and proliferation. Two classes of MHC 
molecules are found on dendritic cells for (cross-) presentation of antigens to T cells: 
Antigens presented on MHC class II receptors are recognized by CD4+ T cells, while 
antigens on MHC class I receptors are cross-presented to CD8+ T cells. In order to 
generate the second activating signal, the interaction between CD28 (expressed on T 
cells) and CD80 or CD86 (expressed on dendritic cells) is essential. To maintain 
clonal T cell expansion, stimulated T cells release IL-2 in an autocrine manner and 
for further differentiation dendritic cells release cytokines such as IL-12.  
 
Figure 6 Representative scheme of the immunological synapse (adapted from 106). 
The interface between a T cell and a mature dendritic cell is termed the ‘immunological synapse’. It is 
built up by multiple interacting molecules on both cells. To establish and stabilize the contact, the 
integrin LFA-1 on the T cell binds ICAM-1 on the dendritic cell. T cell activation by the dendritic cell 
requires the (cross-) presentation of an antigen on MHC molecules to the specific T cell receptor. 
Furthermore, co-stimulatory ligands, such as CD80/CD86 bind to CD28, delivering the second 
activating signal for the T cell. Vice versa, the interaction between CD40 and CD40L delivers an 
activating signal to the dendritic cell. CD83 is a common marker for dendritic cell maturation. DC, 
dendritic cell; ICAM-1, intercellular adhesion molecule 1; LFA-1, lymphocyte function-associated 
antigen 1; MHC, major histocompatibility complex. 
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In the following, the expanding T cells differentiate into effector T cells and leave the 
lymph node. Upon recognition of antigens by the specific T cell receptor, effector T 
cells are activated without a second signal. Therefore, they are potentially able to 
eliminate not only the primary tumor, but also distant metastases. As mentioned in 
chapter 4.1, cytotoxic CD8+ T cells are the most important effector T cells in adaptive 
anti-tumor immunity. They kill target cells via several cytotoxic mechanisms. For 
instance, CD8+ T cells express FasL, which induces apoptosis of target cells upon 
binding to the death receptor Fas expressed on their plasma membrane. Another 
example is the release of the serine protease granzyme B in combination with 
perforin, which may also induce cell death in the target cell. Furthermore, they 
produce IFNγ, thereby enforcing the immune response (e.g. activation of 
macrophages, dendritic cells and T cell differentiation) and enhancing tumor 
immunogenicity (e.g. upregulation of MHC class I molecules).  
In addition to the aforementioned co-stimulatory molecules, various interacting 
proteins expressed on T cells and APCs have been identified 109. Among those, 
activation of CD40 on dendritic cells by CD40L on T cells is noteworthy, because this 
interaction delivers a co-stimulatory signal from the T cell to the APC, resulting in 
increased APC activation 110. Moreover, interactions between CD80/CD86 and PDL-1 
with their corresponding receptors on the T cells – cytotoxic T-lymphocyte-associated 
protein-4 (CTLA-4) and programmed cell death receptor 1 (PD1), respectively –  are 
of special interest, since both cause T cell inhibition, thereby limiting effector T cell 
activity. These mechanisms lead to attenuation of immune responses, and therefore 
protect against autoimmunity and excessive immune responses 111 112. Interestingly, 
both the inhibitory as well as the activating function of CTLA-4 and CD28 are 
dependent on binding to CD80/CD86 on APCs. Ipilimumab, a monoclonal antibody 
directed against CTLA-4, was one of the first immunotherapeutic drugs approved by 
the FDA for the treatment of metastatic melanoma to resolve this endogenous T cell 
inhibition and to strengthen adaptive anti-tumor responses 113. Notably, abscopal 
effects of radiotherapy appear to be more pronounced and more frequent under 
ipilimumab treatment 3. Enhanced surface expression of PDL-1 is not only found on 
regulator APCs, but is also a common mechanism how tumor cells escape 
destruction by effector T cells through binding of PD1 114 115 116. Two monoclonal 
antibodies, nivolumab and pembrolizumab (both approved by the FDA for metastatic 
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melanoma and NSCLC 117 118, interfere with this tumor escape mechanism by binding 
PD1 on T cells. However, ipilimumab as well as nivolumab and pembrolizumab have 
severe side effects such as excessive inflammatory reactions, which need to be 
carefully monitored. 
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5 Objective 
Radiotherapy efficiently induces tumor cell death and, thus, is a mainstay in cancer 
treatment. However, accumulating evidence suggests a contribution of the immune 
system to the radiotherapeutic outcome: Particularly when applied in ablative settings 
(i.e. in high single doses of 10-20 Gy), radiotherapy appears to induce systemic anti-
tumor mechanisms, which are much less frequently observed with classically 
fractionated irradiation regimens (i.e. daily doses of 2 Gy). Yet, the mechanisms 
behind these immunological phenomena remain poorly understood. 
In the present study, central steps governing radiation-induced anti-tumor immunity 
were investigated in the context of fractionated and ablative radiotherapy of breast 
cancer in vitro and in vivo: Induction of tumor cell death, recruitment of monocytes, 
maturation of monocyte-derived antigen-presenting cells, and stimulation of adaptive 
T cell responses were examined in order to understand key elements of radiation-
induced anti-tumor immunity. 
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6 Materials and Methods 
6.1 Materials 
6.1.1 Suppliers 
Table 1. List of suppliers 
Supplier Headquarter of supplier 
ATCC Manassas, VA, USA 
Bachem Bubendorf, Switzerland 
BD Biosciences Heidelberg, Germany 
Biochrom Berlin, Germany 
BioLegend San Diego, CA, USA 
Bio-Rad Hercules, CA, USA 
BioTek Instruments GmbH Bad Friedrichshall, Germany 
Carl Roth Karlsruhe, Germany 
Corning Corning, NY, USA 
eBioscience San Diego, CA, USA 
Enzo Life Sciences Loerrach, Germany 
Eppendorf Hamburg, Germany 
Fermentas St. Leon-Roth, Germany 
GE Healthcare Munich, Germany 
Glaswarenfabrik Karl Hecht Sondheim, Germany 
Greiner BIO-ONE Kremsmuenster, Austria 
ibidi Martinsried, Germany 
IBL International Hamburg, Germany 
Leica Microsystems Wetzlar, Germany 
LI-COR Lincoln, NE, USA 
Life Technologies Karlsruhe, Germany 
Lonza Basel, Switzerland 
New England Biolabs Frankfurt, Germany 
Merck Darmstadt, Germany 
Macherey-Nagel Dueren, Germany 
Microsoft Richmond, WA, USA 
Miltenyi Biotec Bergisch Gladbach, Germany 
Philips Amsterdam, Netherlands 
PromoCell Heidelberg, Germany 
R&D Systems Minneapolis, MN, USA 
ratiopharm Ulm, Germany 
Roche Applied Science Penzberg, Germany 
Sarstedt Nuembrecht, Germany 
Sigma-Aldrich Taufkirchen, Germany 
Thermo Fisher Scientific Waltham, MA, USA 
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Supplier Headquarter of supplier 
Tree Star Inc. Ashland, OR, USA 
Xstrahl Camberley, UK 
Zeiss Goettingen, Germany 
 
6.1.2 Cell lines and culture media 
Table 2. Cell lines 
Cell line Origin Supplier 
BT-474 Human breast cancer ATCC 
BT-549 Human breast cancer ATCC 
HCC1806 Human breast cancer ATCC 
HCC1937 Human breast cancer ATCC 
MCF7 Human breast cancer ATCC 
MDA-MB-468 Human breast cancer ATCC 
   
THP-1 Human acute monocytic leukemia ATCC 
   
HUVECs Primary human endothelial cells PromoCell 
 
Table 3. Cell culture media and supplements 
Medium/Supplement Supplier 
RPMI-1640 Life Technologies 
DMEM Life Technologies 
DMEM/F12 1+1 Life Technologies 
Fetal calf serum (FCS) Life Technologies 
Penicillin/Streptomycin Life Technologies 
HEPES buffer Life Technologies 
Phosphate-buffered saline (PBS) Life Technologies 
Trypsin/EDTA Life Technologies 
  
Endothelial Cell Growth Medium PromoCell 
Supplement Mix PromoCell 
DetachKit PromoCell 
  
X-Vivo 15 Lonza 
Human AB-serum Sigma-Aldrich 
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6.1.3 Reagents, buffers and commercial kits 
Table 4. Reagents and solutions 
Reagent/Solution Supplier 
ATP Sigma-Aldrich 
Annexin V-FITC BD Biosciences 
Annexin staining buffer BD Biosciences 
APS Sigma-Aldrich 
Apyrase New England Biolabs 
ARL-67156 R&D Systems 
Bafilomycin A1 R&D Systems 
Biocoll Separating Solution (1.077 g/ml) Biochrom 
Bradford Reagent Bio-Rad 
BSA Sigma-Aldrich 
C12-FDG Life Technologies 
Calcein-AM Merck 
Anti-CD3 magnetic beads Miltenyi 
Anti-CD14 magnetic beads Miltenyi 
cOmplete™ULTRA Tablets, Mini, EASYpack Roche Applied Science 
Bromophenol blue Sigma-Aldrich 
CFSE Life Technologies 
Cytochalasin D Sigma-Aldrich 
Diluent C Sigma-Aldrich 
dNTPs Fermentas 
EDTA Sigma-Aldrich 
EGTA Sigma-Aldrich 
Ethanol Merck 
FACS staining buffer BD Biosciences 
Fluoromount Sigma-Aldrich 
Formaldehyde Merck 
Glycine Sigma-Aldrich 
Glycoblue Thermo Fisher Scientific 
GM-CSF R&D Systems 
Heparin-Natrium 5000 rathiopharm 
HEPES Sigma-Aldrich 
Hoechst-33342 Sigma-Aldrich 
IGEPAL CA-630 Sigma-Aldrich 
IL-4 R&D Systems 
Isopropanol Merck 
KCl Sigma-Aldrich 
LPS Sigma-Aldrich 
Maxima SYBR Green qPCR Master Mix Thermo Fisher Scientific 
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Reagent/Solution Supplier 
2-Mercaptoethanol Sigma-Aldrich 
Methanol Merck 
MgCl2 Sigma-Aldrich 
Milk powder Carl Roth 
NaCl Sigma-Aldrich 
Nail polish Maybelline 
NaN3 Sigma-Aldrich 
Necrostatin-1 Enzo Life Sciences 
Oligo(dT)18 Fermentas 
PageRuler™ Thermo Fisher Scientific 
Paraformaldehyde Sigma-Aldrich 
Phalloidin-Alexa Fluor568 Thermo Fisher Scientific 
PhosSTOP™ Roche Applied Science 
PKH26 Sigma-Aldrich 
PKH67 Sigma-Aldrich 
2-Propanol Merck 
Propidium iodide (PI) Sigma-Aldrich 
Proteinase K New England Biolabs 
Random hexamers Fermentas 
Revert Aid H Minus M-MuLV reverse 
transcriptase 
Fermentas 
Ribolock RNase inhibitor Fermentas 
Rotiphorese® Gel 30 (37.5:1) Carl Roth 
SDS Sigma-Aldrich 
SDF-1α R&D Systems 
TEMED Carl Roth 
TNF R&D Systems 
Tris Sigma-Aldrich 
Triton-X 100 Sigma-Aldrich 
zVAD-fmk Bachem 
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Table 5. Buffers and gels 
Buffer Reagent Concentration 
Annexin staining buffer (10×) HEPES pH 7.4 0.1 M 
 NaCl 1.4 M 
 CaCl2 25 mM 
 in ddH2O  
Caspase lysis buffer HEPES-K pH 7.4 20 mM 
 KCl 84 mM 
 MgCl2 10 mM 
 EDTA 0.2 mM 
 EGTA 0.2 mM 
 IGEPAL CA-630 0.5% 
 in ddH2O  
FACS stain buffer BSA 2% 
 Sodium azide 0.09% 
 in PBS pH 7.4  
Laemmli buffer (4×) Tris-HCl pH 6.8 250 mM 
 Glycerol 25% 
 SDS 8% 
 Bromophenol blue 0.04% 
 2-Mercaptoethanol 4% 
 in ddH2O  
SDS-PAGE running buffer 
(10×) Tris 250 mM 
 Glycine 1.9 M 
 SDS 1% 
 in ddH2O  
Separation gel Rotiphorese® Gel 30 (30% 
acrylamide, 0.8% bis-acrylamide) 6-15% 
Separation gel buffer 26% 
APS 0.1% 
TEMED 0.08% 
ddH2O ad 100% 
Separation gel buffer Tris-HCl pH 8.8 1.5 M 
 SDS 0.384% 
 in ddH2O  
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Buffer Reagent Concentration 
Stacking gel Rotiphorese® Gel 30 (30% 
acrylamide, 0.8% bis-acrylamide) 5% 
Stacking gel buffer 13.5% 
APS 0.1% 
TEMED 0.08% 
ddH2O ad 100% 
Stacking gel buffer Tris-HCl pH 8.8 1.5 M 
 SDS 0.384% 
 in ddH2O  
Western blot blocking buffer Milk powder 5% 
 in 1× Western blot washing buffer  
Western blot lysis buffer Tris pH 7.6 50 mM 
 NaCl 150 mM 
 Triton-X 100 1% 
 in ddH2O  
 cOmplete™ULTRA tablet 1 tablet per 10 ml 
buffer 
 PhosSTOP™ tablet 
1 tablet per 10 ml 
buffer 
Western blot transfer buffer Tris 44 mM 
 Glycine 40 mM 
 Methanol 20% 
 in ddH2O  
Western blot washing buffer Tris pH 7.5 13 mM 
 NaCl 150 mM 
 Triton-X 100 0.02% 
 in ddH2O  
 
Table 6. Commercial kits 
Kit Supplier 
Bio-Plex Pro Human Chemokine Assay (40-Plex Panel) Bio-Rad 
DuoSet® IC ELISA R&D Systems 
HMGB1-ELISA IBL International 
NucleoSpin® RNA kit II Macherey-Nagel 
TMB Peroxidase EIA Substrate Kit Bio-Rad 
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6.1.4 Antibodies 
Table 7. Antibodies for flow cytometric analyses of human blood cells 
Antibody Color Isotype Supplier Dilution 
CD3 PE-Cy7 Mouse IgG1, κ BD Biosciences 1:50 
CD4 PE Mouse IgG1, κ BD Biosciences 1:25 
CD8 APC Mouse IgG1, κ BD Biosciences 1:25 
CD39 PE Mouse IgG2b, κ BD Biosciences 1:25 
CD40 PE-Cy5 Mouse IgG1, κ BD Biosciences 1:25 
CD73 FITC Mouse IgG1, κ BD Biosciences 1:25 
CD80 PE Mouse IgG1, κ BD Biosciences 1:25 
CD83 PE-Cy7 Mouse IgG1, κ BD Biosciences 1:100 
CD86 Alexa Fluor700 Mouse IgG1, κ BD Biosciences 1:100 
CD203c APC Mouse IgG1, κ BD Biosciences 1:25 
     
Isotype IgG1 Alexa Fluor700 Mouse IgG1, κ BD Biosciences 1:25 
Isotype IgG1 APC Mouse IgG1, κ BD Biosciences 1:25 
Isotype IgG1 FITC Mouse IgG1, κ BD Biosciences 1:25 
Isotype IgG1 PE Mouse IgG1, κ BD Biosciences 1:25 
Isotype IgG1 PE-Cy7 Mouse IgG1, κ BD Biosciences 1:50/1:100 
Isotype IgG1 PE-Cy5 Mouse IgG1, κ BD Biosciences 1:25 
Isotype IgG2b PE Mouse IgG2b, κ BD Biosciences 1:25 
 
Table 8. Antibodies for flow cytometric analyses of mouse blood cells 
Antibody Color Isotype Supplier Dilution 
CD11b FITC Rat IgG2b, κ eBioscience 1:100 
CD11c PerCP-Cy5.5 Arm Ham IgG eBioscience 1:100 
CD45 APC-Cy7 Rat IgG2b, κ BD Biosciences 1:100 
F4/80 eFluor450 Rat IgG2a, κ eBioscience 1:100 
H-2 Alexa Fluor700 Rat IgG2b, κ eBioscience 1:100 
Ly6C PE-Cy7 Rat IgM BD Biosciences 1:100 
Ly6G BUV395 Rat IgG2a, κ BD Biosciences 1:100 
PDCA1 APC Rat IgG2b, κ eBioscience 1:100 
Siglec-H PE Rat IgG2b, κ eBioscience 1:100 
     
Isotype IgG PerCP-Cy5.5 Arm Ham IgG eBioscience 1:100 
Isotype IgG2a BUV395 Rat IgG2a, κ BD Biosciences 1:100 
Isotype IgG2a eFluor450 Rat IgG2a, κ eBioscience 1:100 
Isotype IgG2b Alexa Fluor700 Rat IgG2b, κ eBioscience 1:100 
Isotype IgG2b APC Rat IgG2b, κ eBioscience 1:100 
Isotype IgG2b APC-Cy7 Rat IgG2b, κ BD Biosciences 1:100 
Isotype IgG2b FITC Rat IgG2b, κ eBioscience 1:100 
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Antibody Color Isotype Supplier Dilution 
Isotype IgG2b PE Rat IgG2b, κ eBioscience 1:100 
Isotype IgM PE-Cy7 Rat IgM BD Biosciences 1:100 
 
Table 9. Primary antibodies for western blot analyses 
Antibody Isotype Clonicity Supplier Dilution 
p21WAF1 Mouse IgG1, κ monoclonal BD Biosciences 1:1000 
Vinculin Mouse IgG1, κ monoclonal Sigma-Aldrich 1:1000 
 
Table 10. Secondary antibodies for western blot analyses 
Antibody Reactivity Clonicity Species Supplier Dilution 
IgG-IRDye® 680LT Mouse polyclonal Goat LI-COR 1:20,000 
IgG-IRDye® 800CW Mouse polyclonal Goat LI-COR 1:20,000 
 
Table 11. Antibodies for immunofluorescence staining of human cells 
Antibody Color Isotype Reactivity Supplier Dilution 
E-selectin PE Mouse IgG1, κ Human BD Biosciences 1:25 
ICAM-1 PE Mouse IgG1, κ Human BD Biosciences 1:25 
VCAM-1 PE Mouse IgG1, κ Human BD Biosciences 1:25 
 
Table 12. Antibodies for confocal microscopy of air pouch skins 
Antibody Color Isotype Supplier Dilution 
CD31  
(PECAM-1) 
Alexa Fluor647 Rat IgG2a,  κ BioLegend 1:100 
F4/80 Alexa Fluor488 Rat IgG2a,  κ Thermo Fisher Scientific 1:100 
Ly6G - Rat IgG2a,  κ BioLegend 1:100 
Anti-Rat IgG Alexa Fluor546 Goat IgG Thermo Fisher Scientific 1:400 
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6.1.5 Primers 
Table 13. Primer sequences for quantitative real-time PCR of human samples 
All primers were synthesized by Sigma-Aldrich. 
Gene Primer Sequence 5’-3’ 
18S rDNA Forward CGGCTACCACATCCAAGGAA 
Reverse GCTGGAATTACCGCGGCT 
β2-microglobulin Forward TGCTCGCGCTCATCTCTCTTTC 
Reverse TCTCTGCTGGATGACGTGAGTAAAC 
CX3CL1 Forward ACAGAACCAGGCATCATGCG 
 Reverse CGGGTCGGCACAGAACAG 
CXCL1 Forward AAGCTTGCCTCAATCCTGCAT 
Reverse TGGATTTGTCACTGTTCAGCATCT 
δ-ALAS Forward TCCACTGCAGCAGTACACTACCA 
Reverse ACGGAAGCTGTGTGCCATCT 
Egr-1 Forward GAGCACCTGACCGCAGAGTC 
Reverse CCAGCACCTTCTCGTTGTTCA 
E-selectin Forward CCTACCTGTGAAGCTCCCACTG 
Reverse AGGAGGGAGAGTCCAGCAGC 
HCC1&2 Forward GCGTCAGCGGATTATGGATTAC 
 Reverse ACGGAATGGCCCCTTTTG 
I-309 Forward GCTTGCTGCTAGCTGGGATGT 
 Reverse CTCCGCAAATGAGAAGCAACA 
ICAM-1 Forward GGAACAACCGGAAGGTGTATGA 
Reverse GTTCTGGAGTCCAGTACACGGTG 
IL-1α Forward GCTTCCTGAGCAATGTGAAATACA 
 Reverse CAAATTTCACTGCTTCATCCAGATT 
IL-6 Forward GGTACATCCTCGACGGCATCT 
 Reverse AGTGCCTCTTTGCTGCTTTCAC 
IL-8 Forward TGGCAGCCTTCCTGATTTCT 
Reverse TGCACTGACATCTAAGTTCTTTAGCA 
IP-10 Forward TGGCATTCAAGGAGTACCTCTCT 
 Reverse GTAGCAATGATCTCAACACGTGG 
I-TAC Forward TGTTCAAGGCTTCCCCATGT 
 Reverse GAGGCTTTCTCAATATCTGCCACT 
MCP-1 Forward CAGCAAGTGTCCCAAAGAAGCT 
Reverse TGGAATCCTGAACCCACTTCTG 
MCP-2 Forward GCTGGAGAGCTACACAAGAATCAC 
 Reverse GCCCCGTTTGGTCTTGAA 
MCP-3 Forward GAGAGCTACAGAAGGACCACCAGT 
 Reverse GGGTCAGCACAGATCTCCTTGT 
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Gene Primer Sequence 5’-3’ 
MCP-4 Forward AGGCTGAAGAGCTATGTGATCACC 
 Reverse CCTTGCCCAGTTTGGTTCTG 
MIP-2a  Forward CGCATCGCCCATGGTTAA 
 Reverse CAGTTGGATTTGCCATTTTTCAG 
MIP-2b  Forward CCCATGGTTCAGAAAATCATCG 
 Reverse GTTGGTGCTCCCCTTGTTCA 
p21WAF1 Forward CTGGAGACTCTCAGGGTCGAAA 
Reverse AGTGGTAGAAATCTGTCATGCTGGT 
p53 Forward ATGGAGGAGCCGCAGTCAG 
Reverse TCAGTCTGAGTCAGGCCCTTCT 
P-selectin Forward CCACCAATGTGTGAAGCCATC 
 Reverse TCAGAACAATCCAGGCTGCC 
RANTES Forward CTCTGCGCTCCTGCATCTG 
 Reverse GCGGGCAATGTAGGCAAA 
SDF-1α Forward TGCTGGTCCTCGTGCTGAC 
 Reverse TGGCAACATGGCTTTCGAA 
TNF Forward TCTTCTCGAACCCCGAGTGA 
 Reverse GGAGCTGCCCCTCAGCTT 
VCAM-1 Forward ACGCAAACACTTTATGTCAATGTTG 
Reverse AGCTGCCTGCTCCACAGG 
 
6.1.6 Consumables 
Table 14. Consumables 
Consumable Supplier 
1.5 ml, 2 ml safe-lock tubes Eppendorf 
2 ml, 5 ml, 10 ml, 25 ml, 50 ml stripettes Corning 
6-, 24-, 96-(f/v-bottom) well plates Corning 
15 ml, 50 ml tubes, conical base, PP Sarstedt 
96-well f-bottom solid white plate  Thermo Fisher Scientific 
Cell culture dish, standard, 100 × 12 mm Sarstedt 
Combitips advanced Eppendorf 
epT.I.P.S.  Eppendorf 
FACS tubes, 1.3 ml, PP Greiner BIO-ONE 
Glass tubes, 100 × 12 mm, heavy walled Glaswarenfabrik Karl Hecht 
Immobilon-FL PVDF membrane Merck 
LightCycler 480 Multiwell Plates 96-well Roche Applied Science 
MultiScreen 96-well Transport Receiver Plate Merck 
MultiScreen-MIC Plate 5 µm Merck 
T-75-, T-175-cell culture flasks Corning 
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6.1.7 Equipment and devices 
Table 15. Equipment and devices 
Device Supplier 
AxioObserver Z1 inverted microscope Zeiss 
Bio-Plex 200 Bio-Rad 
LC480 qPCR cycler Roche Applied Science 
Leica TCS SP5 Confocal microscope Leica Microsystems 
LSR II flow cytometer BD Biosciences 
Mueller RT-250 Philips 
NanoDrop 2000c Thermo Fisher Scientific 
Odyssey® CLx infrared imaging system LI-COR 
RS225 X-Ray research irradiator Xstrahl 
SE 400 Vertical Unit for SDS-PAGE GE Healthcare 
Synergy MX fluorescence reader BioTek Instruments GmbH 
Thermomix comfort Eppendorf 
Trans-Blot transfer cell for western blotting Bio-Rad 
 
6.1.8 Software 
Table 16. Software 
Software Version Supplier 
AliBaba 2.1 Niels Grabe 
Excel 2010 Microsoft 
FACSDiva 6.1.3 BD Biosciences 
FlowJo 7.6.3 Tree Star Inc. 
Chemotaxis and Migration 
Tool 
2.0 ibidi 
ImageJ 1.47 Open source 
Origin 9.1 Microcal 
Word 2010 Microsoft 
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6.2 Methods 
6.2.1 Cell culture 
6.2.1.1 Cultivation of cancer cell lines 
BT-474, HCC1806, HCC1937, MCF7 and THP-1 cells were cultured in RPMI-1640 
medium supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin and 10mM HEPES buffer at 37°C and 5% CO2. BT-549 and MDA-MB-
468 cells were cultivated in DMEM and 1+1 DMEM/F12 medium, respectively, 
supplemented with 10% FCS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin at 
37°C and 7.5% CO2. For sub-cultivation and seeding for experiments, cells were 
washed once in PBS and trypsinized at 37°C until a single cell suspension was 
obtained. The trypsinization process was stopped by adding serum-containing cell 
culture medium to the cell suspension in excess. The cells were collected and 
pelleted at 314 g for 5 min. The supernatant was removed, the pellet re-suspended in 
culture medium and the cells were sub-cultivated or used for experiments. 
6.2.1.2 Primary cells 
6.2.1.2.1 Human umbilical vein endothelial cells (HUVECs) 
HUVECs were cultivated in full endothelial growth medium, consisting of Endothelial 
Cell Growth Medium and SupplementMix at 37°C and 5% CO2. Sub-cultivation and 
seeding for experiments was performed as described for the cancer cell lines. 
However, the special DetachKit, containing of HEPES-BSS, Trypsin/EDTA and 
Trypsin Neutralizing Solution, was used for cell detachment: HUVECs were washed 
in HEPES-BSS buffer before trypsinization. The trypsinization process was stopped 
by adding equal amounts of Trypsin Neutralizing Solution to the cell suspension, and 
the centrifugation was performed at 220 g for 3 min. 
6.2.1.2.2 Isolation of human peripheral blood monocytes and T cells 
Primary human peripheral blood monocytes and T cells were isolated from 
heparinized blood from healthy donors by positive selection of CD14+ or CD3+ cells, 
respectively. Heparinized blood was carefully layered on top of the Biocoll Separating 
Solution and centrifuged continuously for 20 min at 787 g with reduced acceleration 
and without brake. Afterwards, the cell layer of peripheral blood mononuclear cells 
(PBMCs) above the Biocoll Separating Solution was collected and washed twice with 
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PBS. The PBMCs were re-suspended to a concentration of 108 cells/ml in ice-cold 
MACS buffer containing 0.5% bovine serum albumin (BSA, Miltenyi). The re-
suspended PBMNCs were incubated with 1× anti-CD14 or anti-CD3 magnetic beads 
(200 µl beads per 108 total cells) on ice for 15 min. Afterwards, cells were washed in 
BSA MACS buffer and loaded onto a pre-washed MACS Column in the magnetic 
field of a MACS Separator. After three washing steps with ice-cold BSA MACS buffer, 
the column was removed from the magnetic field and CD14+ or CD3+ cells were 
eluted with BSA MACS buffer into a glass tube. The eluted cells were washed in X-
Vivo 15 medium, counted, and used for further experiments. 
6.2.2 Cell number determination 
All cell numbers were determined with a Neubauer improved counting chamber. 
Single cell suspensions were pipetted into the chamber, and the cells in the four 
large squares were counted. The mean number of cells within one large square was 
multiplied with the chamber factor 10,000 in order to obtain the density of the cell 
suspension in cells/ml. 
6.2.3 Growth curve analyses and calculation of doubling times 
Cells were seeded into 24-well plates (2.5 × 104 cells per well) in culture medium 
containing 10% FCS and allowed to adhere for 5 h. Medium was replaced by medium 
supplemented with 10% or 2.5% FCS, respectively, and cells were grown for up to 4 
days. On each day, cells were harvested by trypsin treatment and counted. Growth 
curves were generated by plotting log cell number (y-axis) versus time in hours (x-
axis). The slopes of the corresponding regression lines allowed the calculation of 
doubling times according to the formula 
Doubling time  h  log(2)
 time  h 
 log(cells)
 
6.2.4 X-ray treatment and production of cell-free culture supernatants 
Cells were seeded into 6-well (0.5-1 × 106 cells per well) or 24-well plates (0.3-1 × 
105 cells per well) in culture medium containing 10% FCS and allowed to adhere 
overnight. Immediately prior to irradiation, the culture medium was replaced by 
medium containing 2.5% FCS. For initial experiments, X-ray treatment was 
performed on a Mueller RT-250 γ-ray tube. After decommissioning of this device, an 
RS225 X-Ray research irradiator was employed. Both X-ray sources were operated 
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at 200 kV and 10 mA with a Thoraeus filter (0.38 mm Sn, 0.23 mm Cu, 0.99 mm Al). 
The dose rates were 1 min 52 s for 1 Gy using the Mueller RT-250 and 1 min 4 s for 
1 Gy using the RS225. Fractionated irradiation was carried out every 24 h for up to 
four days.  
For the production of cell-free supernatants, culture supernatants were collected from 
the 6-well plates at the indicated time points. In order to remove cell debris, 
supernatants were centrifuged at 10,000 g for 5 min at 4°C and immediately 
transferred into a fresh tube and stored at -80°C for further use. Thawing of 
supernatants for experiments was performed in a ThermoMix at 30°C, 1400 rpm for 
10 min. 
6.2.5 Cell migration analyses 
6.2.5.1 Trans-well migration assay 
The attraction of monocytic cells by irradiated tumor cells and their releasate was 
analyzed by trans-well migration assays with THP-1 cells and cell-free culture 
supernatants of irradiated breast cancer cells. The assays were performed in 96-well 
MultiScreen-MIC trans-well chambers with 5µm pore size. THP-1 cells in log phase 
were adjusted to a concentration of 2 × 106 cells/ml in RPMI-1640 supplemented with 
10% FCS, and labeled with 1 µM Calcein-AM for 20 min at 37°C and 5% CO2. The 
labeled THP-1 cells were washed once in RPMI-1640 supplemented with 10% FCS. 
1 × 105 labeled THP-1 cells per well were seeded in a final volume of 80 µl onto the 
96-well MultiScreen-MIC filter plate. The filter plate was mounted onto the receiver 
plate containing 320 µl of cell-free culture supernatants, 200 nM ATP, or 200 ng/ml 
stromal cell-derived factor 1α (SDF-1α) in serum-free RPMI-1640, respectively. 
Transmigration was allowed for 90 min at 37°C and 5% CO2. Subsequently, the filter 
plate was removed and the transmigrated THP-1 cells in the receiver plate were 
collected at 314 g for 5 min. After discarding 220 µl of supernatant, THP-1 cells were 
re-suspended in the remaining medium and transferred into a 96-well v-bottom plate. 
The v-bottom plate was centrifuged at 314 g for 5 min. The remaining supernatants 
were discarded entirely and the sedimented THP-1 cells were lysed in 100µl caspase 
lysis buffer (see Table 5) for 5 min. The lysates were transferred into a 96-well f-
bottom plate and green Calcein fluorescence was quantified with a Synergy MX 
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fluorescence reader (wavelength=Ex. 480+/- 20 nm, Em. 508+/- 20 nm). 
Transmigrated cells were calculated as percentage of total cells deployed. 
For biochemical characterization of the released monocytic attraction signals, cell-
free culture supernatants were subjected to ultracentrifugation with VivaSpin 2 
centrifuge tubes with an exclusion limit of 10 kDa. Cell-free culture supernatants, 200 
nM ATP and 200 ng/ml SDF-1α were centrifuged at 872 g until the entire liquid phase 
had passed the filter membrane. The filter membrane was rinsed very well with 
culture medium and both fractions (substances smaller or larger than 10 kDa) were 
readjusted to the initial volumes employed. Both fractions were applied to a trans-well 
migration assay. 
For further biochemical characterization, cell-free culture supernatants were treated 
with ATP-diphosphohydrolase (apyrase). Therefore, 500 mU apyrase were added to 
1.5 ml cell-free culture supernatants, 200 nM ATP, or 200 ng/ml SDF-1α, 
respectively. Nucleotide degradation was allowed for 30-50 min at 37°C. Heat-
inactivated apyrase (95°C, 40 min) served as control. After apyrase treatment, 
samples were applied to trans-well migration assays. 
The ectonucleotidase CD39 on MCF7 cells was pharmacologically blocked with 100 
µM ARL-67156. The MCF7 cells were seeded and irradiated with indicated doses. 
Then ARL-67156 was added at a final concentration of 100 µM and refreshed daily. 
Cell-free culture supernatants were produced as described (see chapter 6.2.4) and 
subjected to transmigration assays. 
6.2.5.2 2D chemotaxis assay 
To investigate if the induced trans-well migration behavior of monocytic cells to cell-
free culture supernatants is directed (chemotaxis) or not (chemokinesis), 2D 
chemotaxis assays were set up. Therefore, primary monocytes were isolated as 
described in chapter 6.2.1.2.2 one day before the experiment. After preparation, 
monocytes were seeded in 6-well plates (1 × 106 cells per well) in 2 ml X-Vivo 15 
medium supplemented with 10% autologous serum and incubated overnight at 37°C 
and 5% CO2. The next day, monocytes were collected and re-suspended in X-Vivo 
15 supplemented with 5% autologous serum. 2.5 × 104 monocytes were seeded into 
the observation area of a humidified µ-slide 2D chemotaxis chamber and allowed to 
adhere for 15 min at 37°C and 5% CO2. Non-adherent monocytes were washed 
away and both reservoirs of the chamber were filled with X-Vivo 15 supplemented 
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with 5% autologous serum. Cell-free culture supernatants, 1 µM ATP or 1 µg/ml 
WKYMVm were added into the upper reservoir. The 2D chemotaxis chamber was 
mounted onto the heated stage of the AxioObserver Z1 inverted microscope and 
time-lapse video microscopy was performed at 37°C and 5% CO2 for 3 h at 5× 
magnification. Pictures were taken every 2 min and 40 randomly picked cells were 
tracked with the ImageJ manual tracking plug-in. Analysis window was set from 10 
min to 2 h 10 min (2 h time frame). Accumulated distance, Euclidean distance and y 
forward migration index (yFMI=mean of endpoint y direction/accumulated distance of 
all tracked cells) were determined with the ibidi chemotaxis and migration tool. 
Apyrase treatment of cell-free culture supernatants was performed as described for 
the trans-well migration assays (see chapter 6.2.5.1). 
6.2.6 Flow cytometry 
All flow cytometry measurements were performed with an LSR II flow cytometer and 
data were analyzed with FACSDiva or FlowJo 7.6.3 Software, respectively. 
6.2.6.1 PS externalization and plasma membrane integrity 
During apoptosis, the phospholipid phosphatidylserine (PS) is exposed on the outer 
plasma membrane surface. By interaction of Annexin V-FITC (AnxV-FITC) and PS, 
apoptotic cells can be identified. Loss of plasma membrane integrity is a major event 
during necrosis. Propidium iodide (PI) is a fluorescent DNA intercalator, which does 
not penetrate an intact plasma membrane. Hence, PI can only intercalate into DNA in 
necrotic cells, which have lost plasma membrane integrity. To analyze apoptosis and 
necrosis, cells were seeded into 24-well plates (0.5-1 × 105 cells per well), irradiated 
with the indicated doses (see chapter 6.2.4), and incubated for up to 4 days. Culture 
supernatants were collected, and cells were harvested by trypsinization. After pooling 
both fractions, samples were washed in 1× Annexin staining buffer (diluted in 
ddH2O). Each sample was incubated in 50 µl 1× Annexin staining buffer containing 5 
µl AnxV-FITC and 2 µg/ml PI at 4°C for 15 min. After washing in 1× Annexin staining 
buffer, cells were analyzed by flow cytometry. Cells positive for AnxV-FITC were 
considered as apoptotic and cells double positive for AnxV-FITC and PI as necrotic. 
To distinguish between primary and secondary necrosis, cells were treated with 50 
µM of the poly-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone (zVAD-fmk) 30 min prior to irradiation. Necroptosis was excluded 
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by inhibiting the receptor-interacting protein kinase 1 (RIPK1), a central kinase in the 
necroptotic pathway, with 50 µM necrostatin-1 30 min prior to irradiation. 
6.2.6.2 Senescence-associated β-galactosidase activity 
Upregulation of senescence-associated β-galactosidase (SA-β-gal) and increase in 
granularity are common markers, which can be employed for the identification of 
senescent cells 119. Cells were seeded in 24-well plates (0.5-1 × 105 cells per well) 
and irradiated as described. At the indicated time points after irradiation, cells were 
incubated with 100 nM bafilomycin A1 in serum-free medium for 1 h at 37°C for 
lysosomal alkalization. Subsequently, the green fluorogenic SA-β-gal substrate 5-
dodecanoylamino-fluorescein-di-β-galactopyranoside (C12-FDG) was added at a 
final concentration of 50 µM, and substrate conversion was allowed for 1 h at 37°C. 
After two washing steps with PBS, cells were collected by trypsinization, re-
suspended in PBS and analyzed by flow cytometry. Cells with high FITC and high 
sideward scatter (SSC) signals were considered senescent. 
6.2.6.3 Ectonucleotidase surface expression 
For the detection of ectonucleotidases on the outer cell surface, cells were seeded in 
6-well plates (5 × 105 cells per well) and irradiated as described (see chapter 6.2.4). 
Cells were harvested by trypsinization at the indicated time points, and 2 µl anti-
CD39-PE, anti-CD73-FITC, anti-CD203c-APC or isotype controls were added to 1 × 
105 cells in 50 µl FACS staining buffer. After incubation for 30 min on ice, cells were 
washed twice in FACS staining buffer, and fluorescence of PE, FITC, and APC was 
analyzed by flow cytometry. Relative surface expression was calculated as the 
median fluorescence intensities of anti-ectonucleotidase staining subtracted by the 
corresponding isotype controls. 
6.2.6.4 Dendritic cell surface markers 
To investigate the influence of tumor-derived signals on the differentiation of 
monocytes to dendritic cells, the expression of characteristic dendritic cell surface 
markers (CD40, CD80, CD83, CD86, and HLA-DR) was measured by flow cytometry. 
Primary human peripheral blood monocytes were isolated as described in chapter 
6.2.1.2.2. After isolation, 2 × 105 monocytes per well were seeded into 24-well plates 
in 400 µl serum-free X-Vivo 15 and incubated for 1 h at 37°C and 5% CO2. The 
medium was removed, and monocytes were incubated in 300 µl of conditioned cell-
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free culture supernatants (see chapter 6.2.4) or 200 ng/ml Lipopolysaccharides (LPS) 
(in serum-free X-Vivo 15) for 4 h at 37°C and 5% CO2. Subsequently, 300 µl X-Vivo 
15 supplemented with 20% autologous serum and GM-CSF and IL-4 at final 
concentrations of 20 ng/ml and 40 ng/ml, respectively, were added. Monocytes were 
incubated for 5 days at 37°C and 5% CO2. On day 3 after isolation, GM-CSF and IL-4 
were renewed. Dendritic cells were harvested by trypsinization on day 5. After 
trypsinization, dendritic cells were washed with ice-cold FACS staining buffer and 
transferred into a 96-well v-bottom plate on ice. 2 µl of anti-CD40-PE-Cy5, anti-
CD80-PE, and 0.5 µl of anti-CD83-PE-Cy7, anti-CD86-Alexa Fluor700 or isotype 
controls for a total volume of 50 µl in FACS staining buffer were added followed by 
incubation for 30 min on ice in the dark. Thereafter, dendritic cells were washed twice 
in FACS staining buffer, and fluorescence of PE-Cy5, PE, PE-Cy7, and Alexa 
Fluor700 was analyzed by flow cytometry. Relative surface marker expression was 
calculated as described for ectonucleotidase expression (see chapter 6.2.6.3). The 
fold increase was calibrated on the 0 Gy sample. 
Biochemical characterization of tumor-derived signals influencing CD80 expression 
was carried out as described for the trans-well migration assays (see chapter 
6.2.5.1). LPS was used as a positive control. Instead of apyrase, the cell-free culture 
supernatants were digested with the protein-degrading enzyme Proteinase K 
(20 µg/ml) for 30 min at 37°C. 
Furthermore, the influence of tumor-derived signals on the maturation of 
differentiated dendritic cells was investigated. Therefore, monocytes were isolated as 
described before in the differentiation assay. However, monocytes were first 
differentiated to dendritic cells for 5 days in X-Vivo 15 supplemented with 10% 
autologous serum and 20 ng/ml GM-CSF and 40 ng/ml IL-4, before cell-free culture 
supernatants or 100 nM TNF (in serum-free X-Vivo 15) were added, respectively. 
The treatment protocol and the FACS analysis were performed analogously to the 
differentiation assay. 
6.2.6.5 Phagocytosis assay 
Phagocytosis of irradiated HCC1937 breast cancer cells by dendritic cells was 
analyzed by co-incubation of both cell types stained with different fluorescent dyes. 
Human peripheral blood monocytes were isolated as described in chapter 6.2.1.2.2. 
After isolation, monocytes were stained with the green membrane labeling dye 
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PKH67. Therefore, monocytes were diluted in Diluent C to a concentration of 4 × 107 
cells/ml in a glass tube and PKH67 was added at a final concentration of 1 µM. 
Monocytes were stained for 1.5 min. The staining process was stopped by diluting 
the reaction 1 + 1 with 100% FCS.  
After 1 min, monocytes were washed in X-Vivo 15 supplemented with 10% 
autologous serum and seeded into a T75 flask. For the differentiation of monocytes 
to dendritic cells, 20 ng/ml GM-CSF and 40 ng/ml IL-4 were added. Monocytes were 
incubated for 5 days at 37°C and 5% CO2, whereby GM-CSF and IL-4 were renewed 
3 days after isolation. On the day of monocyte isolation, HCC1937 cells were stained 
with the orange cell membrane labeling dye PKH26 according to the PKH67 staining 
protocol for monocytes. However, HCC1937 cells were diluted to a concentration of 2 
× 107 cells/ml, PKH26 was added at a final concentration of 2 µM, and staining was 
allowed for 5 min. The stained HCC1937 cells were seeded into 24-well plates (3-10 
× 104 cells per well) in RPMI-1640 medium supplemented with 10% FCS. On the 
next day, labeled HCC1937 were irradiated with the indicated doses (see chapter 
6.2.4). On day 5 after monocyte isolation and HCC1937 seeding, dendritic cells were 
collected and co-incubated with the irradiated HCC1937 cells at the indicated ratios 
(target to effector cells T:E) for 2 h at 37°C and 5% CO2. After co-incubation, cells 
were collected by trypsinization and analyzed by flow cytometry. Percentage of 
phagocytosis was calculated as the percentage of PKH67/PKH26 double-positive 
dendritic cells on the basis of all dendritic cells deployed (positive for PKH67). Active 
phagocytosis of HCC1937 cells by dendritic cells was confirmed by treatment with 
cytochalasin D, an inhibitor of actin filament polymerization. Dendritic cells were 
treated with 20 µM cytochalasin D 1 h before co-incubation with HCC1937 cells. 
6.2.6.6 Allogeneic mixed leukocyte reaction 
Apart from dendritic cell differentiation and phagocytosis, the influence of tumor-
derived signals on the induction of T cell proliferation by dendritic cells was studied. 
To this end, human peripheral blood monocytes and T cells were isolated as 
described in chapter 6.2.1.2.2 from two allogeneic blood donors. After isolation, 
monocytes were allowed to adhere in 6-well plates (1 × 106 cells per well) for 1 h in 2 
ml serum-free X-Vivo 15 at 37°C and 5% CO2. The medium was removed, and 
monocytes were incubated in 1.5 ml cell-free culture supernatants, 100 ng/ml TNF, or 
serum-free X-Vivo 15 for 4 h, respectively. Afterwards, dendritic cell differentiation 
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was initiated by adding 20 ng/ml GM-CSF and 40 ng/ml IL-4 in 1.5 ml X-Vivo 15 
supplemented with 20% autologous serum. GM-CSF and IL-4 were renewed on day 
3 and 5 after isolation. On day 7 after isolation, dendritic cells were detached by 
adding 1 ml ice-cold 5 mM EDTA in PBS and incubation for 5 min on ice. Detached 
dendritic cells were collected and washed in serum-free X-Vivo 15. 2 × 104 dendritic 
cells per well were seeded into a 96-well f-bottom plate in 100 µl serum-free X-Vivo. 
On the same day as dendritic cell seeding, T cells were isolated from an allogeneic 
blood donor. After washing in serum-free X-Vivo 15, T cells were re-suspended in 
prewarmed (37°C) 0.1% BSA in PBS at a final concentration of 1 × 106 cells/ml and 
stained with 0.5 µM of the green fluorescent dye CFSE for 10 min at 37°C. Staining 
was stopped by adding an excessive volume of ice-cold serum-free X-Vivo 15 to the 
T cells, following incubation on ice for 5 min. CFSE-stained T cells were washed 
three times in serum-free X-Vivo 15 and finally re-suspended in X-Vivo 15 
supplemented with 20% human AB-serum to a concentration of 1 × 106 cells/ml. 100 
µl of the T cell suspension were added to the dendritic cells (DC to T cell ratio=1:5) 
and both cell types were co-incubated for 5 days at 37°C and 5% CO2. Afterwards, T 
cells were collected and washed in PBS. T-cells were re-suspended in 100 µl ice-
cold FACS staining buffer and transferred into 96-well v-bottom plates. After 
centrifugation (314 g, 5 min, 4°C), the supernatants were discarded, and 1 µl of anti-
CD3-PE-Cy7, 2 µl of anti-CD4-PE, and 2 µl of anti-CD8-APC or isotype controls in 50 
µl FACS staining buffer were added to the T cells. Antibody binding was allowed for 
30 min on ice in the dark. Subsequently, T cells were washed twice in FACS staining 
buffer, and fluorescence of CFSE, PE-Cy-7, PE, and APC was analyzed with the flow 
cytometer. Since CFSE is distributed equally to the two daughter cells of a dividing T 
cell, loss of CSFE fluorescence intensity is a marker for cell proliferation. The 
percentage of proliferated CD4+ and CD8+ T cells was calculated as the amount of 
CD3+CFSElowCD4+ or CD3+CFSElowCD8+ cells on the basis of all CD3+CD4+ or 
CD3+CD8+ cells, respectively. The fold increase in T cell proliferation was calibrated 
on the 0 Gy sample. 
6.2.6.7 Leukocyte infiltration into air pouches 
The different subsets of myeloid cells infiltrating into the air pouches in response to 
HCC1937 cell-free culture supernatants were analyzed by flow cytometry. Therefore, 
air pouches on the back of 9-10 weeks old female Balb/c mice were generated and 
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stimulated as described in chapter 6.2.9. At indicated time points, mice were 
euthanized, and the pouches were washed three times with physiological saline 
solution (154 mM NaCl). The washing solutions were combined, and infiltrated cells 
were pelleted (314 g, 5 min). Cell pellets were washed in FACS staining buffer and 
re-suspended in 500 µl FACS staining buffer for cell counting (see chapter 6.2.2). 
Afterwards, 0.1 to 0.5 × 106 cells were stained either with 0.5 µl of anti-CD45-APC-
Cy7, anti-CD11b-FITC, anti-CD11c-PerCP-Cy5.5, anti-F4/80-eFluor450, anti-Ly6C-
PE-Cy7, anti-Ly6G-BUV395, anti-H-2-Alexa Fluor700, anti-PDCA1-APC, and anti-
Siglec-H-PE or isotype controls in 50 µl FACS staining buffer for 20 min on ice in the 
dark. Stained cells were washed twice with FACS staining buffer, re-suspended in 
100 µl FACS staining buffer, and subjected to flow cytometry. The gating strategy for 
the discrimination of different leukocyte subsets is shown in Figure 7. 
 
Figure 7 Gating strategy for the discrimination of infiltrating myeloid subpopulations. 
Within all CD45+ cells (after doublet discrimination), CD11b+ cells were determined to identify 
leukocytes of the innate immune system. Among these, neutrophils (Ly6G+F4/80-) and macrophages 
(Ly6C-F4/80+) were identified. To distinguish between dendritic cells and monocytes, CD11c 
expression was used. Among dendritic cells (CD11c+), plasmacytoid dendritic cells (Siglec-H+PDCA1+) 
and myeloid dendritic cells (F4/80-H-2+) were subclassified. Monocytes (CD11c-) were divided into the 
two known murine subsets by their Ly6C expression: Inflammatory (Ly6Chi) and resident (Ly6Clow). 
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Absolute cell numbers of each leukocyte subset were calculated on the basis of all 
CD45+ cells. To obtain absolute CD45+ cell numbers, measured CD45+ cells of each 
sample were normalized on measured singlet events and multiplied by the total cell 
numbers obtained from the air pouch lavages. The absolute numbers of each 
leukocyte subset were calculated on the basis of the leukocyte subset percentage 
(ratio between measured leukocyte subset events and CD45+ events of each sample) 
multiplied by absolute CD45+ cell numbers.  
6.2.7 Molecular biology 
6.2.7.1 RNA extraction and quantification 
Total RNA was extracted from cells by using the NucleoSpin® RNA kit II according to 
the supplier’s protocol. Breast cancer cells were seeded into 6-well plates (0.5-2 × 
106 cells per well) in medium supplemented with 10% FCS and irradiated with the 
indicated doses as described (see chapter 6.2.4). After incubation for the indicated 
times, medium was removed, cells were washed with ice-cold PBS and collected with 
a rubber spatula on ice. Cell suspensions were transferred into 2 ml tubes on ice, 
centrifuged (16,200 g, 5 min, 4°C) and dry cell pellets were stored at -80°C. For RNA 
isolation, the cell pellets were lysed in 350 µl RA1 buffer (from the NucleoSpin® RNA 
kit II) supplemented with 1% 2-Mercaptoethanol. Nucleic acids were precipitated with 
70% ethanol and bound to a silica membrane. Subsequently, the membrane was 
desalted, and contaminating DNA was digested with rDNase for 15 min at room 
temperature. The samples were washed three times and eluted in RNase-free H2O. 
The concentration and purity of the extracted RNA was measured on a NanoDrop 
2000c UV-Vis spectrometer. The RNA concentration was calculated based on 
Lambert-Beer’s law with the absorption of the RNA solution at 260 nm and the 
specific extinction coefficient for a pure RNA solution at a concentration of 40 ng/ml. 
The purity of the RNA solution is described by the ratio of the solution’s absorption at 
260 nm and 280 nm (A260/A280 ratio). An A260/A280 ratio between 1.7 and 2.0 is 
generally defined as pure for RNA solutions. The isolated RNA was stored at -80°C 
for further use. 
For preparation of HUVEC RNA after incubation with the relevant stimuli, 
supernatants were removed, and cells were directly lysed in 350 µl RA1 buffer from 
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the NucleoSpin® RNA kit II supplemented with 1% 2-Mercaptoethanol. Subsequent 
RNA extraction was done as described for breast cancer cells. 
6.2.7.2 Reverse transcription 
To obtain cDNA for quantitative real-time PCR, 1 µg of RNA was reversely 
transcribed with 200 U Revert Aid H Minus M-MuLV reverse transcriptase in the 
presence of 50 µM random hexamers, 5 µM Oligo(dT)18, 400 µM dNTPs, and 1 U/µl 
Ribolock RNase inhibitor. First, RNA was mixed with random hexamers, Oligo(dT)18, 
and dNTPs and heated to 65°C for 15 min. After chilling on ice, reverse transcriptase 
and RNase inhibitor, both provided in reaction buffer, were added to the RNA. For 
reverse transcription, samples were incubated at 25°C for 10 min, following heating 
to 42°C for 60 min allowing reverse transcription, and heat inactivation at 72°C for 10 
min. The synthesized cDNA was stored at -20°C until further use. 
6.2.7.3 Quantitative real-time PCR 
The expression levels of genes of interest (see Table 13) were analyzed by 
quantitative real-time PCR. 20-80 ng cDNA were mixed with 300 nM forward and 
reverse primers (sequences see Table 13), and 1× Maxima SYBR Green qPCR 
Master Mix. Real-time PCRs were performed with a standard cycling protocol (10 min 
95°C, 45 × (15 s 95°C, 30 s 60°C)) on an LC480 qPCR cycler. Relative quantification 
was performed using the standard curve method and results were normalized to the 
means of 18S rRNA, β2-microglobulin, and δ-ALAS. The fold increase was calculated 
on the basis of the respective medium sample. 
6.2.8 Protein methods 
6.2.8.1 SDS-PAGE 
2-4.5 × 106 cells were seeded in cell culture dishes in medium supplemented with 
10% FCS and irradiated on the next day as described in chapter 6.2.4. At the 
indicated time points, cells were collected with a rubber spatula on ice and 
transferred into 2 ml tubes. After washing with ice-cold PBS, dry cell pellets were 
stored at -80°C until lysis. 1 × 106 Cells were lysed in 100 µl western blot lysis buffer 
(see Table 5) for 20 min on ice with occasional vortexing. Lysates were cleared by 
centrifugation (16,200 g, 10 min, 4°C) and transferred to fresh tubes on ice. 
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To determine the protein content of the cell lysates, Bradford protein assays 120 were 
performed. For protein quantification, an 8-point BSA standard curve (0-300 µg/ml in 
PBS) was used. Cell lysates were diluted with H2O to appropriate concentrations in 
the range of the standard curve. Bradford standards and cell lysates were mixed with 
1× Bradford Reagent in a ratio of 1:50 (final volume 250 µl) in a 96-well f-bottom plate 
and incubated for 5 min at room temperature. The absorption was measured at 595 
nm. Protein concentrations of cell lysates were intrapolated from the standard curve. 
300 µg protein per sample was used for gel electrophoresis.  
Denaturing, reducing gel electrophoresis for separation of proteins was carried out on 
linear gradient gels with an acrylamide content of 6-15%. Two separation gels with 
6% and 15% acrylamide were prepared by mixing separation gel buffer (pH 8.8, see 
Table 5), and an appropriate amount of Rotiphorese® Gel 30 (30% acrylamide, 0.8% 
bis-acrylamide) in ddH2O. Polymerization was started by addition of 0.1% APS, and 
catalyzed by 0.08% TEMED (see Table 5). Both separation gel mixtures were 
transferred into a gradient mixer connected with the gel apparatus. After casting, the 
gradient separation gel was covered with 2-propanol and polymerization was allowed 
for 1 h. After polymerization, 2-propanol was discarded, and the top of the separation 
gel was washed with H2O. For the stacking gel, stacking gel buffer (pH 6.8, see Table 
5), and an appropriate amount of Rotiphorese® Gel 30 (30% acrylamide, 0.8% bis-
acrylamide) were mixed in ddH2O. Polymerization was started by addition of 0.1% 
APS, catalyzed by 0.08% TEMED (see Table 5), and the stacking gel was cast onto 
the separation gel. A comb was placed into the stacking gel to create sample slots, 
and polymerization was allowed for 20 min. The gel was mounted into the gel 
electrophoresis chamber, and buffer reservoirs were filled with 1× SDS-PAGE 
running buffer (see Table 5). Samples were mixed with Laemmli buffer (final: 1× 
concentrated, see Table 5), boiled at 95°C for 5 min, spun down (16,200 g, 5 min) 
and loaded into the stacking gel slots with a Hamilton syringe. For the estimation of 
protein size, a pre-stained protein ladder (PageRuler™) was used. Electrophoresis 
was run with 800 Vh until the bromophenol blue front had reached the lower edge of 
the gel. 
6.2.8.2 Western blotting and immunodetection 
Following separation by gel electrophoresis, proteins were transferred onto 
Immobilon-FL PVDF membranes employing a tank-blot system from Bio-Rad. PVDF 
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membranes were equilibrated in 100% methanol, washed in H2O and rinsed in 1× 
western blot transfer buffer without methanol (see Table 5). The western blot 
sandwich was assembled according to the supplier’s protocol and protein transfer 
was allowed for 2 h at 4°C at 0.5 A in western blot transfer buffer supplemented with 
20% methanol. After protein transfer, PVDF membranes were blocked with western 
blot blocking buffer (see Table 5) for 1 h at room temperature. The blocked 
membranes were washed twice in western blot washing buffer (see Table 5), and 
incubated with primary monoclonal mouse anti-p21WAF1 (1:1000) or anti-vinculin 
(1:1000) antibodies overnight at 4°C. Thereafter, membranes were washed three 
times and incubated with the corresponding secondary IRDye-conjugated antibody 
(1:20,000) for 1 h at room temperature. Finally, after extensive washing in western 
blot wash buffer, IRDye fluorescence was read with an LI-COR Odyssey® CLx 
infrared imaging system. 
6.2.8.3 Immunofluorescence microscopy of important adhesion molecules on 
HUVECs 
All immune fluorescence pictures were recorded on an AxioObserver Z1 inverted 
microscope at 63× magnification. The immune fluorescence staining procedure of the 
adhesion molecules ICAM-1, VCAM-1 and E-selectin on HUVECs was carried out 
without fixation on native cells. HUVECs were seeded onto sterile cover slips into 24-
well plates (4 × 104 cells per well) in full endothelial growth medium and incubated at 
37°C and 5% CO2. After 48 h of adherence, HUVECs were incubated with 400 µl of 
conditioned cell-free culture supernatants diluted 1:2 in full endothelial growth 
medium, 50 ng/ml TNF, or full endothelial growth medium, respectively, for 4 h at 
37°C and 5% CO2. HUVECs were washed carefully with FACS staining buffer before 
they were stained with 6 µl of anti-ICAM-1-PE, or anti-VCAM-1-PE or anti-E-selectin-
PE and Hoechst-33342 (1:500) in 150 µl FACS staining buffer for 30 min on ice in the 
dark. HUVECs were washed twice with FACS staining buffer and mounted with 5 µl 
Fluoromount. The cover slips were sealed upside down onto glass slides with nail 
polish before microscopy. 
6.2.8.4 Quantification of ICAM-1 expression on HUVECs 
Surface expression of ICAM-1 on HUVECs was carried out as described for the 
immunofluorescence microscopy of adhesion molecules. However, HUVECs were 
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seeded in 96-well f-bottom plates (9,000 HUVECs per well) in full endothelial growth 
medium and incubated up to 48 h at 37°C and 5% CO2. Induction of ICAM-1 with 
190 µl of 1:2 diluted cell-free culture supernatants and controls was carried out as 
described in chapter 6.2.8.3. HUVECs were washed carefully in FACS staining buffer 
and incubated with 2 µl of anti-ICAM-1-PE or isotype in 50 µl FACS staining buffer for 
30 min at 4°C in the dark. HUVECs were washed twice with FACS staining buffer, 
and PE-fluorescence was measured on a Synergy Mx plate reader (wavelength=Ex. 
480+/- 20 nm, Em. 578+/- 20 nm). Relative surface expression of ICAM-1 was 
calculated by subtraction of the fluorescence intensity of the matching isotype control, 
and the fold increase was calibrated on the 0 Gy sample. 
6.2.8.5 Multiplex immunoassays 
The concentrations of cytokines and chemokines released from HUVECs in response 
to tumor-derived signals were measured on a Bio-Plex 200 System. The panel of 
reactants is shown in Table 17. Assays were performed according to the 
manufacturer’s protocol with commercial 1 × 96 well kits (see Table 6 and Table 17). 
The commercial kits included standards, the detection antibody, reagents and buffers 
needed for the Multiplex assays. For sample generation, HUVECs were seeded and 
treated with 1:2 diluted cell-free culture supernatants or controls as described for the 
qRT-PCR experiments (see chapter 6.2.7.1). After 4 h incubation, supernatants were 
harvested as described in chapter 6.2.4 and stored at -80°C until analysis. 50 µl of 
HUVEC supernatant were incubated with 2.5-5 µl chemokine-binding beads for 1 h at 
room temperature. Following three washing steps, 1.25-2.5 µl biotinylated detection 
antibody was added in 25 µl diluent buffer, and samples were incubated for 30 min at 
room temperature. Subsequently, the biotinylated detection antibody was bound by 
PE-labeled streptavidin (1:10 in assay buffer) and samples were measured in the 
Bio-Plex 200 system. 50 beads per region within the doublet discriminator gates 
(5,000-25,000) were recorded per sample. Chemokine concentrations were 
calculated on the basis of the standard curves formerly cleared from outliers. 
Table 17. Measured chemokines in the Bio-Plex Pro Human Chemokine Assay 
CCL3 CCL15 CCL17 CCL19 CCL20 CCL22 CCL23 CCL25 
CX3CL1 CXCL1 CXCL2 CXCL6 CXCL9 CXCL16 Eotaxin-1 Eotaxin-2 
Eotaxin-3 GM-CSF HCC1/2 I-309 IL-1β IL-2 IL-4 IL-6 
IL-8 IL-10 IL-16 IFNγ IP-10 I-TAC MCP-1 MCP-2 
MCP-3 MCP-4 MIF MIP-2a RANTES SDF-1α TNF  
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6.2.8.6 ELISA 
6.2.8.6.1 Detection of HSP70 
HSP70 levels in the supernatants of dying HCC1937 cells were measured with the 
DuoSet® IC ELISA kit from R&D Systems according to the supplier’s protocol. 
Reagents, buffers, and antibodies necessary for the ELISA were included in the 
DuoSet® IC kit. The substrate solution for the color reaction was a 9:1 mixture of 
Solution B and Solution A from the TMB Peroxidase EIA Substrate kit (see Table 6). 
Briefly, cell-free culture supernatants of irradiated HCC1937 cells were produced as 
described in chapter 6.2.4. Each incubation step of the ELISA was carried out at 
room temperature (except the capture antibody coating) and, after each incubation, 
the 96-well plate was washed three times with washing buffer. One day before 
analysis, a 96-well f-bottom solid white plate was coated with 100 µl capture antibody 
(2 µg/ml) per well at 4°C in the dark overnight. On the day of the ELISA, the coated 
96-well plate was blocked for 2 h with 100µl blocking buffer. Samples were diluted 
1:10 in serum-free RPMI-1640 medium and 100 µl were transferred into the blocked 
96-well plate. After incubation for 2 h, the 96-well plate was incubated with 100 µl of 
biotinylated detection antibody (100 ng/ml) per well for another 2 h. For the color 
reaction, 100 µl streptavidin coupled HRP (1:200) per well were added into the 96-
well plate for 20 min. The substrate solution was mixed as mentioned above, 100 µl 
were added, and substrate conversion was allowed for 20 min. The color reaction 
was terminated with 50 µl stopping solution before reaching saturation, and 
absorption was measured at 450 nm on the Synergy Mx reader. HSP70 
concentrations were calculated by using an 8-point standard curve of purified human 
HSP70 (0-10 ng/ml). 
6.2.8.6.2 Detection of HMGB1 
For the quantification of HMGB1 released from irradiated HCC1937 cells, the 
HMGB1-ELISA kit from IBL International was used. The kit included a pre-coated 96-
well microtiter plate and all reagents and buffers necessary for the HMGB1-ELISA. 
All steps were carried out according to the supplier’s protocol. The incubation steps 
were carried out at room temperature. Cell-free culture supernatants of HCC1937 
cells were produced as described in chapter 6.2.4. In the HMGB1-ELISA, 100 µl 
diluent buffer per well were added to a pre-coated 96-well microtiter plate and 10 µl 
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of standards, a positive control (pig HMGB1), and cell-free culture supernatants (1:5 
diluted in serum-free RPMI-1640) were added after incubation for 24 h, the plate was 
washed five times with 1× washing buffer and 100 µl enzyme conjugate were added 
to each well. 2 h later, the plate was washed again five times and samples were 
exposed to the color solution for 25-30 min. The color reaction was terminated with 
stopping solution, and absorption was measured at 450 nm on the Synergy Mx. 
Concentrations of HMGB1 in cell-free culture supernatants were calculated using a 7-
point standard curve (0-80 ng/ml). 
6.2.8.6.3 Detection of S100A8/A9 
The detection of S100A8/A9 in cell-free culture supernatants of irradiated HCC1937 
cells was kindly performed by Prof. Dr. Thomas Vogl at the Institute of Immunology of 
the University of Muenster, Muenster, Germany, according to their inhouse ELISA 
protocol 121. 
6.2.9 The air pouch mouse model 
In order to determine the attraction of myeloid cells by supernatants of irradiated 
HCC1937 cells in vivo, the air pouch mouse model was used 122. For pouch 
generation, the backs of 9-10 weeks old female BALB/c mice were depilated before 5 
ml of sterile air were injected subcutaneously. After 3 days, 3 ml sterile air were 
reinjected. At day 7 after pouch generation, 1 ml of cell-free culture supernatants of 
HCC1937 cells 4 days after irradiation (see chapter 6.2.4) was injected into the air 
pouches. As negative and positive control, 1 ml of RPMI-1640 supplemented with 
2.5% FCS, and 1 ml of 50 ng/ml mouse TNF in RPMI-1640 supplemented with 2.5% 
FCS were used, respectively. At the indicated time points, pouches were lavaged 3x 
with 2 ml saline, and the resulting cell suspensions were subjected to FACS analyses 
of leukocyte subsets (see chapter 6.2.6.7 In addition to the air pouch lavage, the skin 
of each air pouch was isolated for further confocal microscopy studies of leukocyte 
subsets (see chapter 6.2.10). 
Throughout the experiments, mice received water and food ad libitum, and mice were 
kept in individual cages at standard conditions (humidity 55-65%, temperature 22-
24°C) with a 12 h day/night cycle. All studies were performed in accordance to the 
guidelines of the Federation of European Laboratory Animal Science Associations 
(FELASA) and were approved by the Regierung von Oberbayern. 
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6.2.10 Confocal microscopy of air pouch skin 
For confocal microscopy of leukocyte subsets, the air pouch skin samples were fixed 
in 3.5% paraformaldehyde (in 1× PBS) for 1 h. The fixed air pouch skin samples were 
handed to Dr. Gabriele Zuchtriegel from the Walter Brendel Centre of Experimental 
Medicine, Klinikum der Universität München, Munich, Germany, who kindly 
performed the staining and confocal microscopy on a Leica TCS SP5 Confocal 
microscope. The fixed skin samples were washed in 1× PBS and permeabilized in 
0.1% Triton X-100 containing 2% BSA at 4°C overnight. On the next day, the 
permeabilized samples were stained with 1:100 diluted anti-CD31-Alexa Fluor647 
(detection of vessels), anti-F4/80-Alexa Fluor488 (detection of 
monocytes/macrophages), and anti-Ly6G (detection of neutrophils) antibodies at 4°C 
for 72 h. The stained samples were washed three times in 1× PBS, and the 
secondary anti-Rat IgG-Alexa Fluor546 antibody was added (1:400) for visualization 
of Ly6G. After 3 h of incubation at room temperature, the samples were washed three 
times in 1× PBS, and embedded in PermaFluor mounting medium between 
microscope slides and cover slips. After drying at room temperature, confocal 
microscopy was performed. 
6.2.11 Statistical analyses 
Data are presented as means ± standard deviation, unless stated otherwise. 
Statistical significance was tested by two-tailed, unpaired Student’s t-test or ANOVA; 
p-values <0.05 were considered as significant. For determination of linear correlation 
between distinct values, Pearson’s correlation coefficient was calculated. Principal 
component analysis was carried out in OriginPro 9.1 as previously described 123. 
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7 Results 
7.1 Different breast cancer cell lines vary in p53 status and doubling 
time 
To cover the spectrum of breast cancer varieties, a panel of three breast cancer cell 
lines with different molecular subtypes, varying in hormone receptor and epidermal 
growth factor receptor expression as well as p53 status, was chosen (Figure 8A).  
 
Figure 8 Breast cancer cell lines of different origin vary in doubling time and p53 functionality 
(adapted from 124). 
(A) List of breast cancer cell lines used in the present study. Molecular subtype, tumor type, and 
receptor expression pattern have been described 124. The p53 mutational status was determined by 
cDNA sequencing. (B) Growth curves of breast cancer cell lines were investigated in the presence of 
2.5% or 10% FCS, respectively. Means ± s.d. of triplicates are shown. (C) Doubling times of breast 
cancer cells calculated on the basis of the data shown in (B). (D) p53 functionality was verified by 
induction of p21WAF1 in whole cell lysates after irradiation with 4Gy at the indicated time points by 6-
15% SDS-PAGE (300µg protein extract per lane) followed by immunoblot analysis. Vinculin served as 
a loading control. 
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BT-474 and MCF7 cells represent a common form of breast cancer in elderly women 
and with good prognosis (estrogen receptor positive, with or without Her2 
overexpression and p53 mutated or wild-type, respectively), while HCC1937 cells 
represent an aggressive form of breast cancer, mostly found in young women with 
poor prognosis (i.e. tumor growth is independent of hormone receptors and Her2/neu 
overexpression (triple-negative phenotype), and mutated p53). 
The mutation status of p53 in the three breast cancer cell lines was determined by 
cDNA sequencing. The functionality of p53 was verified by irradiation-induced 
upregulation of the p53 target p21WAF1 (Figure 8D). Starting 4 h after irradiation with 
4 Gy, an increase in p21WAF1 protein levels was observed in the p53 wild-type cell 
line MCF7. This increase was stable for up to 12 h after irradiation. In BT-474 and 
HCC1937 cells, both mutated in p53, irradiation did not induce an increase in 
p21WAF1 as expected. The proliferation rates of the three cell lines showed clear 
differences with short (MCF7), intermediate (HCC1937) and long (BT-474) doubling 
times in the presence of 2.5% FCS (Figure 8B, C). Hence, the differences between 
breast cancer cells of distinct origin are mirrored not only by varying expression of 
hormone/growth receptors and p53 mutation status, but also by proliferation rate. 
7.2 Breast cancer cell lines respond differently to distinct ionizing 
radiation regimens 
Next, the cellular responses of the breast cancer cells to ionizing radiation were 
investigated. With regard to the clinical practice, single low dose (1 × 2 Gy), 
fractionated (4 × 2 Gy), and ablative (1 × 20 Gy) irradiation was performed. Non-
irradiated cells served as a control. Induction of apoptosis, necrosis, and senescence 
was measured flow cytometrically for 1 to 4 days upon irradiation (Figure 9A). 
Primary and secondary (post-apoptotic) necrosis were distinguished by using the 
poly-caspase inhibitor zVAD-fmk, which impedes apoptosis and the subsequent 
transit into secondary necrosis (Figure 9B). The necroptosis inhibitor necrostatin-1 
was employed to delineate the contribution of necroptosis (Figure 9C). There were 
clear differences in the cell death profiles of the three cell lines: Slow-proliferating BT-
474 cells showed very low levels of apoptosis or primary or secondary necrosis after 
irradiation. 
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Figure 9 Induction of apoptosis, necrosis, and senescence by ionizing radiation in different 
breast cancer cell lines is dependent on the irradiation regimen (modified from 124) 
(A) Induction of apoptosis, necrosis, and senescence in breast cancer cell lines was measured by flow 
cytometry over 4 days after irradiation. Cells were irradiated with 2 Gy, daily 2 Gy, and 20 Gy or left 
untreated as control. Apoptosis and necrosis were determined by Annexin V-FITC/PI staining. Annexin 
V-FITC positive, PI negative cells were considered as apoptotic, Annexin V-FITC/PI double positive 
cells as necrotic. Senescence induction was measured by SA-β-gal staining with the fluorogenic 
substrate C12-FDG. Cells with high SSC and high C12-FDG signal were considered senescent. 
Means ± s.d. of triplicates are shown. (B) Determination of secondary necrosis. Apoptosis and 
necrosis induction were measured as in (A) in the presence of 50 µM of the poly-caspase inhibitor 
zVAD-fmk. Means ± s.d. of triplicates are shown. (C) Determination of necroptosis. Apoptosis and 
necrosis induction were measured as in (A) in the presence of 50 µM of the necroptosis inhibitor 
necrostatin-1. Means ± s.d. of triplicates are shown. 
 
A strong induction of primary necrosis was observed in HCC1937 cells after ablative 
irradiation, and fast-proliferating MCF7 cells revealed a strong increase in apoptosis, 
especially after ablative irradiation, and, consequently, high levels of secondary 
necrosis. However, MCF7 cells also underwent primary necrosis after ablative 
irradiation to a comparable extent as HCC1937 cells did. None of the cell lines 
showed relevant levels of necroptosis, but induction of senescence was clearly 
detectable in all three cell lines, particularly after ablative irradiation. In conclusion, 
the most prominent cell death effects were observed in fast-proliferating breast 
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cancer cells after ablative irradiation. In cells with wild-type p53, a combination of 
apoptosis, primary, and secondary (post-apoptotic) necrosis was the major 
consequence, whereas cells lacking functional p53 mainly underwent primary 
necrosis and senescence. 
7.3 Dying breast cancer cells can attract monocytic cells 
One of the first steps in the induction of an adaptive immune response is the 
recruitment of antigen-presenting cells (APCs) to sites of pathogen invasion or tissue 
damage, where pathogen- and/or danger-associated molecular patterns (PAMPs or 
DAMPs, respectively) are enriched. APCs are attracted by ‘find-me’ signals released 
from dying cells 125. To examine the APC attracting potential of dying breast cancer 
cells, cells were irradiated with the aforementioned radiation regimens, and 
conditioned cell-free culture supernatants were subjected to transmigration assays 
with the monocytic cell line THP-1 (Figure 10A). Time-dependent transmigration of 
THP-1 cells was observed with supernatants of ablatively irradiated HCC1937 cells. 
The extent of THP-1 transmigration paralleled the levels of primary necrosis in 
HCC1937 cells (see Figure 9). Attraction of THP-1 cells by supernatants generated 
upon fractionated irradiation was significantly lower than in case of supernatants of 
ablatively irradiated cells. Importantly, culture supernatants of irradiated BT-474 or 
MCF7 cells only marginally attracted THP-1 cells, irrespective of the radiation 
regimen and incubation time applied. Since BT-474 cells did not show any 
measurable cell death induction upon radiation (see Figure 9), this result was 
expected. However, the extent of primary (and secondary) necrosis in MCF7 cells 
after ablative irradiation was comparable to that of HCC1937 cells (see Figure 9), but 
THP-1 cell attraction was not observed. Before addressing this issue, the biochemical 
composition of the attraction signals released from HCC1937 cells was further 
characterized. Numerous dying cell-derived ‘find-me’ signals have been described in 
the literature 9. The molecular entities range from proteins (e.g. HSP70, HSP90, 
HMGB1) to small molecules, such as nucleotides (e.g. ATP, UTP) and monosodium 
urate crystals. 
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Figure 10 Primary necrotic, fast-proliferating and p53 mutated irradiated breast cancer cells 
attract monocytic cells by releasing nucleotides after irradiation (adapted from 124). 
(A) Trans-well migration of THP-1 cells to cell-free culture supernatants of irradiated HCC1937, MCF7, 
and BT-474 cells. Breast cancer cells were irradiated as in Figure 9, and supernatants were isolated 
on day 1-4 after irradiation. Means ± quadruplicates are shown. Asterisks indicate p<0.05 as 
determined by unpaired Student’s t-test (20 Gy vs. daily 2 Gy). (B) Biomolecular characterization of 
monocytic attraction signals. Cell-free culture supernatants of HCC1937 cells irradiated with 20 Gy 
were collected on day 4 after irradiation, and subsequently subjected to ultracentrifugation with 
Vivaspin 2 columns (molecular weight cut-off 10 kDa) or apyrase treatment (33.3 milliunits active or 
heat-inactivated apyrase/ml, 30 min at 37°C). Culture medium supplemented with 200 nM ATP or 200 
ng/ml SDF-1α served as controls. After treatment, supernatants were subjected to trans-well migration 
assays with THP-1 cells. The percentage of transmigrated cells was normalized on the corresponding 
untreated samples. Means ± s.d. of quadruplicates are shown. (C) Additional breast cancer cell lines 
used in the present study. The molecular subtype, the tumor type, and the receptor expression have 
been described 124. The p53 mutational status was determined by cDNA sequencing. HCC1806 cells 
gave no PCR product, but the mutation in codon 256 was described in the literature 124. (D) Growth 
curves of additional breast cancer cell lines were determined as in Figure 8. (E) Necrosis induction ± 
50µM zVAD-fmk was measured at the indicated doses as in Figure 8. Means ± s.d. of triplicates are 
shown. (F) Trans-well migration of THP-1 cells to cell-free culture supernatants of irradiated MDA-
MB468, HCC1806, and BT-549 cells. Cell-free culture supernatants of irradiated breast cancer cells 
were collected on day 4 after irradiation and subjected to trans-well migration assays with THP-1 cells 
as in (A). Means ± s.d. of quadruplicates are shown. (G) Fast-proliferating breast cancer cells undergo 
primary necrosis after ablative irradiation as revealed by Pearson’s correlation analysis between 
doubling time and percentage of primary necrosis on day 4 after ablative irradiation. (H) Fast-
proliferating, p53 mutated breast cancer cells showing a strong induction of primary necrosis upon 
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ablative irradiation are the source of monocytic attraction signals. Pearson’s correlation analysis was 
performed between percentage of transmigration and primary necrosis on day 4 after ablative 
irradiation. 
 
For biochemical characterization of the responsible attraction signals in our 
experimental setting, ultracentrifugation against a membrane with 10 kDa cut-off and 
apyrase (nucleotide-diphosphatase) digestion were performed with HCC1937 
supernatants collected 4 days after ablative irradiation. ATP (apyrase-sensitive, 
Mw=507 Da) and SDF-1α (apyrase-insensitive, Mw=11 kDa) served as controls. The 
results show that ablatively irradiated, necrotic HCC1937 cells release apyrase-
sensitive compounds with an apparent molecular weight <10 kDa, which are 
responsible for THP-1 attraction (Figure 10B). Hence, nucleotides appear to be the 
relevant ‘find-me’ signals in this scenario.  
To confirm the conclusions of the transmigration assays, three additional cell lines 
with comparable properties to HCC1937 cells, i.e. triple-negative and p53 mutant, 
were chosen (Figure 10C). HCC1806 and MDA-MB-468 cells revealed short doubling 
times similar to HCC1937 cells, whereas BT-549 had a slow-proliferation rate similar 
to that of BT-474 cells (Figure 10D). Fast-proliferating HCC1806 and MDA-MB-468 
cells showed high levels of primary necrosis after ablative irradiation, while slow-
proliferating BT-549 cells did not (Figure 10E). Correlation analyses between the 
extent of primary necrosis induction and doubling time revealed that the faster cells 
proliferated, the more primary necrosis was induced after ablative irradiation (Figure 
10G). Transmigration assays with cell-free culture supernatants of BT-549, 
HCC1806, and MDA-MB-468 cells collected 4 days after irradiation confirmed the 
observation that only fast-proliferating cells (HCC1806 and MDA-MB-468) release 
THP-1 attraction signals, preferentially upon ablative irradiation (Figure 10F). Since 
(primary) necrotic cells are known to release ‘find-me’ signals, the positive correlation 
between THP-1 cell migration and the percentage of primary necrotic cells suggests 
that primary necrotic cells are the source of the attraction signals (Figure 10H).  
In summary, fast- but not slow-proliferating, triple-negative, and p53 mutant breast 
cancer cells predominantly undergo primary necrosis, particularly after ablative 
irradiation. Primary necrosis is accompanied by the release of nucleotides which in 
turn attract monocytic cells. 
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7.4 Monocytic cell attraction is prevented by ectonucleotidases 
expressed on dying, p53 wild-type breast cancer cells 
Although MCF7 cells are fast-proliferating, and high levels of primary necrosis are 
induced by ablative irradiation (see Figure 8, Figure 9), they do not release THP-1 
cell attracting 'find-me' signals (Figure 10). Considering that nucleotides were 
identified as the responsible monocytic attraction signals, the expression of 
nucleotide-degrading enzymes (i.e. ectonucleotidases) on the surface of BT-474, 
HCC1937, and MCF7 cells was investigated (Figure 11).  
 
 
Figure 11 Nucleotide-guided transmigration is abrogated by upregulation of CD39 in MCF7 
cells upon irradiation (adapted from 124). 
(A) Relative CD39 surface expression on breast cancer cell lines after irradiation with the indicated 
doses. Flow cytometric measurements were performed on day 4 after irradiation. Relative 
fluorescence was calculated as the medians of anti-CD39 staining subtracted by corresponding 
isotype controls. Means ± s.d. of triplicates are shown. (B) Trans-well migration of THP-1 cells to cell-
free culture supernatants of irradiated MCF7 cells after pharmacological inhibition of CD39. Upon 
irradiation with the indicated doses, 100 µM of the CD39 inhibitor ARL-67156 were added to MCF7 
cells and refreshed daily. MCF7 supernatants were collected up to 4 days after irradiation, and 
subjected to trans-well migration assays. Means ± s.d. of quadruplicates are shown. (C) In silico 
analysis of the CD39 promotor revealed putative binding sites for the female sexual hormone 
receptors (ER, PR), as well as Sp-1, Egr-1, Stat3, and members of the fork head transcription factor 
family (Fox). (D) Time-course analysis of p21WAF1 (upper panel) and Egr-1 (lower panel) mRNA 
expression in breast cancer cell lines upon irradiation. mRNA was isolated on day 0-4 after irradiation 
with the indicated doses and analyzed by qRT-PCR. Results were normalized on the means of 18S 
rRNA and β2-microglobulin and calibrated on the d 0 controls. Means of duplicates are shown. 
 
In contrast to HCC1937 and BT-474, the ectonucleotidase CD39 was already basally 
expressed on MCF7 cells, and its expression level increased strongly in a time- and 
dose-dependent manner upon irradiation (Figure 11A). Inhibiting CD39 with the small 
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molecule inhibitor ARL-67156 restored THP-1 cell migration towards cell-free 
supernatants of ablatively irradiated MCF7 cells suggesting that extracellular 
nucleotides released by necrotically dying MCF7 cells are degraded by CD39, thus 
preventing monocyte attraction (Figure 11B).  
The mechanisms responsible for the differences of CD39 expression between MCF7, 
HCC1937 and BT-474 cells are poorly understood. Putative binding sites for 
transcription factors were identified in the promotor region of CD39 by in silico 
analysis using the AliBaba 2.1 platform (Figure 11C). Among those, estrogen and 
progesterone receptor binding sites were found. These hormone receptors are 
suitable candidates for the regulation of CD39 expression, since MCF7 cells are 
positive for both. Yet, BT-474 cells are also hormone receptor positive (see Figure 8), 
but do not express CD39. In contrast to BT-474 cells, MCF7 cells possess wild-type 
p53. It has been reported that the estrogen receptor and p53 can act coordinately as 
regulators of target gene expression 126 127 128, hence providing an explanation for the 
basal expression of CD39 on MCF7 cells. The irradiation-induced increase in CD39 
expression on MCF7 cells might as well depend on functional p53 (and the estrogen 
receptor), because p53 is activated upon irradiation. This activation was confirmed by 
the upregulation of the p53 target p21WAF1 on mRNA and protein level (Figure 11D). 
Another transcription factor, whose binding site was found within the CD39 promotor 
is Egr-1. Egr-1 expression is known to be induced by ionizing radiation 129 as 
confirmed by our qRT-PCR analyses (Figure 11D), thus strengthening the role of 
Egr-1 as potential candidate which modulates ionizing radiation-induced upregulation 
of CD39. 
Taken together, irradiation-induced expression of the ectonucleotidase CD39 in 
MCF7 cells is apparently responsible for the degradation of dying cell-derived, THP-1 
attracting nucleotides. 
7.5 In vitro attraction of monocytic cells by nucleotides released from 
primary necrotic breast cancer cells is not directed 
Leukocyte attraction to sites of infection or inflammation is finely regulated by 
directional signals, i.e. attraction signal gradients. However, trans-well migration 
assays do not allow any conclusion concerning the directionality of migration 
(directed vs. not directed). This question was addressed in 2D chemotaxis assays, in 
which migration paths of individual cells can be delineated (Figure 12).  
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Figure 12 Nucleotides released from necrotic HCC1937 breast cancer cells induce undirected 
migration of monocytes in vitro (adapted from 124). 
(A) Chemotaxis/chemokinesis of primary human monocytes to cell-free culture supernatants of 
irradiated HCC1937 cells. HCC1937 cells were treated with the indicated doses. On day 4 after 
irradiation, cell-free culture supernatants were collected and subjected to 2D chemotaxis/chemokinesis 
assays with primary human monocytes. Live-cell tracking was performed in ibidi µ-slide chemotaxis 
2D chambers for 2 h. ATP (1 µM) and the FPR-agonist WKYMVm (1 µg/ml) served as controls. 
Trajectory paths of 40 randomly picked cells are shown. Monocytes with net migration in the direction 
of the gradient are depicted in black, those with net migration in opposite direction are depicted in red. 
The center of mass is represented by the filled blue circle. (B) Parameters of monocyte migration 
behavior. Trajectory paths of 40 randomly picked cells as shown in (A) were analyzed for accumulated 
distance, Euclidean distance (linear distance between start- and endpoint of migration), and forward 
migration index in y-direction to the gradient (yFMI=endpoint in y-direction/accumulated distance). 
Time frame for analysis was 2 h. Bars indicate the median values of 40 cells analyzed. p-values were 
determined by unpaired Student’s t-test against 0 Gy. (C) Chemokinesis-inducing attraction signals 
are apyrase-sensitive. Cell-free culture supernatants of HCC1937 cells, irradiated with 20 Gy, were 
harvested on day 4 after irradiation, and treated with apyrase (33.3 milliunits active or heat-inactivated 
apyrase/ml, 30 min at 37°C). Subsequently, 2D chemotaxis/chemokinesis assays with primary human 
monocytes were performed as in (A). (D) The accumulated distance was analyzed as in (B). Bars 
indicate the median values of 40 randomly cells analyzed. p-values were determined by unpaired 
Student’s t-test against 0 Gy. 
 
Here, the migratory behavior of primary human monocytes towards cell-free 
supernatants of irradiated HCC1937 cells was similar to that of the ATP control: Cells 
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migrated faster and over longer distances than in the not irradiated controls, but 
migration was not directed as compared to the chemotactic formyl-peptide receptor 
agonist WKYMVm (Figure 12A). Accumulated and euclidean distances were 
significantly increased with cell-free supernatants of irradiated HCC1937 cells in 
comparison to the not irradiated controls. However, the forward migration index 
(yFMI) as a measure of directionality was clearly positive only for WKYMVm. Again, 
the strongest effects were seen when cell-free supernatants of ablatively irradiated 
HCC1937 cells were used as stimulus (Figure 12B). Apyrase digestion virtually 
abrogated migration of primary human monocytes towards cell-free supernatants of 
ablatively irradiated HCC1937 cells (Figure 12C, D).  
In conclusion, monocyte migration stimulated by necrotic cell-derived nucleotides 
upon irradiation is not chemotactic, but rather chemokinetic (i.e. non-directional). 
Alone, nucleotides obviously fail to orchestrate directional leukocyte migration – a 
finding which has also been reported by others 130 55. However, the obtained data 
were generated in vitro. In vivo, other mediators and cell populations might well 
contribute to directional leukocyte recruitment by dying cancer cells. 
7.6 Cells of the innate immune system are recruited by dying breast 
cancer cells in vivo 
To investigate the attraction potential of cell-free supernatants of irradiated HCC1937 
cells in vivo, an air pouch model was used. Supernatants were injected into the air 
pouches of BALB/c mice, and infiltrating myeloid cell populations were examined 
over 3-24 h (Figure 13). Confocal microscopy analyses of the airpouch skin revealed 
a clear accumulation of Ly6G+ neutrophils, probably infiltrated from the small vessels 
into the tissue, as early as 3 h after supernatant injection, which further increased 
during the next 3 h (Figure 13A). 12 h after injection, neutrophils gradually 
disappeared, and a substantial increase in F4/80+ monocytes/macrophages was 
detected until 24 h after injection. 
Importantly, clear differences between the injected supernatants were observed: 
Whereas supernatants of non-irradiated HCC1937 cells induced infiltration of 
neutrophils and monocytes/macrophages only marginally and to a comparable extent 
as unconditioned control medium did, supernatants of irradiated HCC1937 cells led 
to a strong infiltration of myeloid cell subsets, particularly in case of the ablative and 
the fractionated irradiation regimens.  
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Figure 13 Neutrophils and monocyte subsets are actively recruited by supernatants of 
irradiated breast cancer cells in vivo. 
In the air pouch mouse model, 1 ml of supernatants of irradiated HCC1937 cells (collected 4 days after 
irradiation with the indicated doses) was injected into the pouches of Balb/c mice (n=6 per radiation 
treatment schedule). Fresh culture medium (n=2) and TNF (50 ng/ml, n=2) served as controls. (A) 
Representative confocal microscopy pictures of air pouch skin samples after injection of the indicated 
supernatants. Air pouch skin samples were isolated 3 h, 6 h, 12 h, and 24 h after injection. Upon 
fixation and permeabilization, air pouch skin samples were stained with primary anti-F4/80-Alexa 
Fluor488 for the visualization of macrophages (green), anti-CD31-Alexa Fluor647 for endothelial cell 
surface staining (blue), and anti-Ly6G combined with secondary anti-rat IgG-Alexa Fluor546 for the 
visualization of neutrophils (red). (B) Flow cytometric analyses of leukocyte infiltration into air pouches. 
The pouch lavages were collected at the indicated time points after injection and infiltrating leukocyte 
subsets were stained against various surface markers for flow cytometric analysis. For greater detail 
and gating strategy, see Figure 7. Panels from left to right: Time-dependent infiltration of CD45+ 
leukocytes, neutrophils, Ly6Chi monocytes, and Ly6Clow monocytes into air pouches are shown in total 
numbers. Means ± s.e.m are depicted. Comparison of curves from irradiated samples to 0 Gy was 
performed by two-way ANOVA. Data of additional leukocyte subsets are not shown. 
 
Quantitative flow cytometry analyses of the pouch lavages further strengthened the 
observations from confocal microscopy (Figure 13B). The numbers of CD45+ cells 
that were recruited into the air pouches clearly increased over time, with a maximum 
around 6 h after injection. Later on, CD45+ cell numbers decreased again reaching 
baseline levels 24 h after injection. Apart from the positive control TNF, the strongest 
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effects were observed with supernatants of ablatively irradiated HCC1937 cells. 
CD45+ cell recruitment was clearly attenuated with supernatants of fractionatedly 
(4x2 Gy) and single low dose (2 Gy) irradiated cells, and it was basically not 
detectable with supernatants of non-irradiated controls. Subclassification of CD45+ 
cells into neutrophils and monocytic subsets (Ly6Clow and Ly6Chi) revealed that 
neutrophils were the dominating cell fraction, and that the kinetic pattern was similar 
to that of all CD45+ cells. In contrast, Ly6Chi and Ly6Clow monocytes, which were 
recruited in smaller but well detectable absolute numbers, displayed a delayed 
infiltration pattern reaching a maximum 12 h after supernatant injection. Only in case 
of Ly6Clow but not for Ly6Chi monocytes recruitment by supernatants of ablatively 
irradiated exceeded recruitment stimulated by supernatants of fractionatedly 
irradiated cells. 
Taken together, neutrophils and monocytes are potently recruited by supernatants of 
irradiated breast cancer cells into air pouches in vivo, and the highest numbers of 
infiltrating myeloid cells are observed with supernatants of ablatively irradiated 
samples. The question that arises at this point is how directionless chemokinesis as 
observed in vitro can be converted into directional recruitment in vivo. 
7.7 Endothelial cells are activated by proteins released from dying 
breast cancer cells 
A conditio sine qua non in leukocyte recruitment is the activation of endothelial cells. 
This includes upregulation of adhesion molecules and the release and/or deposition 
of distinct cytokines and chemokines on the luminal surface of the endothelium 81. To 
analyze this aspect in the context of breast cancer radiotherapy, primary human 
umbilical vein endothelial cells (HUVECs) were treated with cell-free supernatants of 
irradiated HCC1937 cells, as well as TNF as positive and unconditioned medium as 
negative control. Surface expression of the adhesion molecules E-selectin, ICAM-1 
and VCAM-1 was visualized by immunofluorescence (Figure 14A).  
Clear differences between the radiation regimens were observed: HUVECs treated 
with supernatants of 2 Gy and daily 2 Gy irradiated HCC1937 cells showed only 
limited upregulation of E-selectin, ICAM-1, and VCAM-1 on their surface. In contrast, 
HUVECs exposed to supernatants of ablatively irradiated HCC1937 cells strongly 
upregulated E-selectin, ICAM-1, and VCAM-1 expression on their surface. Signal 
quantification for ICAM-1 clearly showed that supernatants of 2 Gy and daily 2 Gy 
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irradiated HCC1937 cells had only moderate, whereas supernatants of ablatively 
irradiated HCC1937 cells had strongest effects on adhesion molecule expression on 
HUVECs (Figure 14B). 
 
 
Figure 14 Endothelial cells are activated by dying breast cancer cell-derived protein DAMPs. 
HUVECs were exposed for 4 h to cell-free culture supernatants of irradiated HCC1937 cells collected 
on day 4 after irradiation. Supernatants were diluted 1:2 in endothelial growth medium prior to HUVEC 
exposure. Endothelial growth medium alone and TNF (50 ng/ml) served as controls. (A) 
Representative immune fluorescence pictures of HUVECs after incubation with indicated samples. For 
immune fluorescence microscopy, HUVECs were natively stained with anti-ICAM-1-PE (upper row; 
red), anti-VCAM-1-PE (middle row; red), or anti-E-selectin-PE (lower row; red), respectively. Nuclei 
were visualized by Hoechst-33342 staining (blue). (B) Quantification of ICAM-1 expression on 
HUVECs after exposure to supernatants or respective controls. The fold increase in ICAM-1 surface 
expression was calculated as the means of fluorescence intensities of anti-ICAM-1 staining subtracted 
by the corresponding isotype controls and normalized to the results of the 0 Gy samples. Means ± s.d. 
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of six biological replicates are shown. Asterisks indicate p<0.05 as determined by unpaired Student’s 
t-test against 0 Gy. (C) HUVEC-activating factors in supernatants of irradiated HCC1937 cells are 
larger than 10 kDa and Proteinase K-sensitive. On day 4 after irradiation, cell-free culture 
supernatants of HCC1937 cells irradiated with 20 Gy were subjected to ultracentrifugation with 
Vivaspin 2 columns (molecular weight cut-off 10 kDa) or Proteinase K treatment (20 µg/ml active or 
heat-inactivated Proteinase K, 30 min at 37°C), and subsequently exposed to HUVECs. TNF 
(50ng/ml) served as positive control. ICAM-1 surface expression was measured as in (B). Means ± 
s.d. of five to six biological replicates are shown. Asterisks indicate p<0.05 as determined by unpaired 
Student’s t-test against 0 Gy. (D) mRNA expression analyses of adhesion molecules and cytokines in 
HUVECs after stimulation by cell-free culture supernatants of irradiated HCC1937 cells and respective 
controls. mRNA was isolated 4 h after exposure to indicated samples, and analyzed by qRT-PCR. 
Results were normalized on the means of 18S rRNA, β2-microglobulin, and δ-ALAS, and calibrated on 
the respective medium samples. Four biological replicates per treatment schedule were analyzed. (E) 
Dimensionality reduction of mRNA expression data was performed by principal component analysis 
(PCA). The eigenvectors of cytokine mRNAs are depicted in the subspace of the first two PCs (black 
coordinate system). The loadings are depicted in the green coordinate system. (F) Quantification of 
cytokines released from HUVECs after exposure to the indicated samples. HUVEC supernatants were 
collected 4 h after stimulation and subjected to multiplex protein measurements. Concentrations of 
depicted proteins were calculated on the basis of standard curves. Medians ± s.d. of triplicates are 
shown. Asterisks indicate p<0.05 as determined by unpaired Student’s t-test against 0 Gy. Data of 
additional cytokines are not shown. 
 
Notably, biochemical characterization of the responsible molecular entities within the 
culture supernatants by size exclusion filtration and protease digestion identified 
proteins >10 kDa to be responsible for the upregulation of ICAM-1 on HUVECs 
(Figure 14C). Increase in ICAM-1, VCAM-1, and E-selectin was not only detected on 
the surface expression level but also on the transcript level as measured by qRT-
PCR. Again, HUVECs treated with supernatants of ablatively irradiated HCC1937 
cells showed the strongest effects (Figure 14D). 
In addition to adhesion molecule expression, cytokines and chemokines can be 
produced and released by activated endothelial cells in order to recruit distinct 
leukocyte subpopulations. These cytokine/chemokine gradients guide leukocytes to 
sites of inflammation or damage, respectively. To address this issue, mRNA levels of 
cytokines and chemokines known to be involved in the attraction and activation of 
leukocytes and general inflammation were measured in HUVECs after incubation 
with conditioned supernatants of HCC1937 cells, TNF, or unconditioned medium as 
controls, respectively (Figure 14D). qRT-PCR analyses revealed a heterogenic 
picture with different cytokines/chemokines being up- or downregulated depending 
on the treatment (e.g. MCP-2, CXCL1), and others being only marginally influenced 
(e.g. MCP-4, RANTES). Apart from the positive control TNF, supernatants of 
ablatively irradiated HCC1937 cells induced the strongest effects within the group of 
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upregulated cytokines/chemokines, while these increases in case of supernatants of 
fractionatedly or 2 Gy irradiated HCC1937 cells were clearly attenuated. This pattern 
was seen for IL-8, MCP-1, MCP-2, MCP-3, CXCL1, IP-10, MIP-2a, MIP-2b, and IL-6. 
In order to better identify possible patterns of cytokine/chemokine expression for 
each treatment, relative expression levels were subjected to principal component 
analysis (Figure 14E). Notably, three clusters were obtained: (i) the TNF samples, (ii) 
the 20 Gy samples, and (iii) the remaining samples, including 0 Gy, 2 Gy, daily 2 Gy, 
and unconditioned medium. On the mRNA level, the response of HUVECs to TNF 
stimulation was characterized by a pleiotropic panel of produced 
cytokines/chemokines. In contrast, exposure to 20 Gy supernatants stimulated a 
response in HUVECs which was mainly defined by (in descending order) IL-6, MIP-
2a, CXCL1, MCP-3, and MIP-2b. IL-6 is one of the master regulators of inflammation 
131. It affects not only cells of the innate and adaptive immune system, but also 
activates the acute phase response, and stimulates systemic effects such as fever. 
MIP-2a and CXCL1 are both well known chemoattractants for neutrophils 52. 
Next, it was examined whether the increase in IL-6, MIP-2a, CXCL1, MCP-3, and 
MIP-2b expression on the mRNA level was also translated to the protein level. 
Indeed, multiplex ELISA measurements in HUVEC supernatants after incubation with 
conditioned media of irradiated HCC1937 cells revealed elevated levels of IL-6, MIP-
2a, CXCL1, and MCP-3 in comparison to the non-irradiated control (Figure 14F). 
Unfortunately, detection reagents for MIP-2b were commercially not available for this 
experimental setup. However, the measured chemokine levels revealed the same 
pattern as had already been observed on mRNA level: Strongest effects with 
supernatants of 20 Gy irradiated HCC1937 cells, equally low effects with 
supernatants of single 2 Gy and fractionatedly irradiated HCC1937 cells. This pattern 
was consistently noticed also with other chemokines found in the HUVEC 
supernatants: IL-8, MCP-1 (both were also increased on mRNA level), and MIF. IL-8, 
MCP-1, and MIF have been shown to be essential not only for neutrophil but also for 
monocyte recruitment 97. Moreover, IL-1β and diverse other cytokines/chemokines 
(data not shown), all following the described pattern, were found in the HUVEC 
supernatants after exposure to conditioned media of irradiated HCC1937 cells. 
In summary, these data support the notion that proteins which are released from 
irradiated HCC1937 cells activate endothelial cells to express adhesion molecules on 
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their surface and to produce and secrete cytokines and chemokines – both essential 
processes for the directional recruitment of neutrophils and monocytic cells. Adhesion 
molecule expression and cytokine generation by HUVECs were strongest after 
incubation with supernatants of ablatively irradiated HCC1937 cells, while 
supernatants of 2 Gy and daily 2 Gy irradiated cells showed clearly more subtle 
effects. Intriguingly, the cytokine/chemokine response of HUVECs to supernatants of 
ablatively irradiated HCC1937 cells was unique and different from that induced by 
TNF suggesting that high single dose irradiation of breast cancer cells may induce 
distinct immunological mechanisms different from prototypical, TNF-driven 
inflammation. 
7.8 Monocytic cell differentiation and dendritic cell maturation are 
influenced by protein DAMPs released from dying breast cancer 
cells 
In the context of anthracycline-based chemotherapy it was shown that, apart from 
leukocyte recruitment, dying cancer cells can stimulate the differentiation of intra-
tumoral monocytes into antigen-presenting cells and subsequently initiate adaptive 
anti-tumor immune responses 132 133. Along this line, the influence of tumor cell-
derived material released from primary necrotic cells after irradiation on monocyte 
differentiation and dendritic cell maturation was evaluated. Important markers of the 
immunological synapse were monitored on monocytes and dendritic cells upon 
exposure to conditioned media of irradiated HCC1937 cells. These markers included 
the co-stimulatory ligands CD80 and CD86, the co-stimulatory receptor CD40, the 
dendritic cell maturation marker CD83, and the MHC class II receptor HLA-DR.  
In the differentiation approach, isolated monocytes were incubated with cell-free 
supernatants of irradiated HCC1937 cells and the respective controls (LPS and 
serum-free X-Vivo 15 medium) followed by treatment with GM-CSF and IL-4 for 5 
days to stimulate dendritic cell differentiation. FACS analyses revealed that the 
expression of CD86, CD40, CD83, and MHC class II was elevated on dendritic cells 
after treatment with cell-free supernatants of irradiated HCC1937 cells in comparison 
to supernatants of untreated control cells (Figure 15A). The most prominent effect in 
this regard was seen for CD80 expression. Supernatants of ablatively irradiated 
HCC1937 cells led to the strongest upregulation of CD80, while cell-free 
supernatants of 2 Gy and daily 2 Gy irradiated HCC1937 cells showed clearly less 
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effects. The signals released from irradiated HCC1937 cells that were responsible for 
CD80 upregulation were sensitive to proteinase K treatment and predominantly 
exhibited an apparent molecular weight of >10 kDa as disclosed by biochemical 
characterization (Figure 15B). 
 
 
Figure 15 Expression of prominent surface markers on monocyte-derived dendritic cells is 
modulated by dying tumor cell-derived protein DAMPs. 
(A) Flow cytometric analysis of the surface markers CD80, CD86, CD40, CD83, and HLA-DR on 
monocyte-derived dendritic cells. Primary human monocytes were stimulated for 4 h with supernatants 
of irradiated HCC1937 cells, collected on day 4 after irradiation. LPS (200 ng/ml) was used as a 
positive control. Following stimulation, monocytes were differentiated to dendritic cells by GM-CSF (20 
ng/ml) and IL-4 (40 ng/ml) treatment over 5 days, and subsequently subjected to flow cytometry. The 
fold increase in surface marker expression was calculated as the means of fluorescence intensities of 
anti-surface marker staining subtracted by the corresponding isotype controls and normalized on the 
results of the 0 Gy samples. Means ± s.d. of five biological replicates are shown. Asterisks indicate 
p<0.05 as determined by unpaired Student’s t-test against 0 Gy. (B) CD80 upregulation is mediated by 
Proteinase K-sensitive proteins released from irradiated HCC1937 cells. Cell-free culture supernatants 
of HCC1937 cells irradiated with 20 Gy were collected on day 4 after irradiation and subjected to 
ultracentrifugation with Vivaspin 2 columns (molecular weight cut-off 10 kDa) or Proteinase K 
treatment (20 µg/ml active or heat-inactivated Proteinase K, 30 min at 37°C). Afterwards, primary 
human monocytes were stimulated with the treated samples, and CD80 surface expression was 
measured as in (A). LPS (200 ng/ml) served as a positive control. Means ± s.d. of eight to ten 
biological replicates are shown. Asterisks indicate p<0.05 as determined by unpaired Student’s t-test 
against 0 Gy. (C) Flow cytometric analysis of the marker panel from (A) on differentiated dendritic 
cells. Primary human monocytes were differentiated to dendritic cells with GM-CSF (20 ng/ml) and IL-
4 (40 ng/ml) for 5 days. On day 5, dendritic cells were stimulated with cell-free supernatants of 
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irradiated HCC1937 cells as in (A). TNF (100 ng/ml) served as a positive control. 2 days after 
stimulation, surface marker expression was analyzed by flow cytometry. The fold increase of surface 
markers was calculated as in (A). Means ± s.d of five biological replicates are shown. Asterisks 
indicate p<0.05 as determined by unpaired Student’s t-test against 0 Gy. (D) For biochemical 
characterization of HCC1937-derived factors responsible for CD80 upregulation, supernatants of 
HCC1937 cells, irradiated with 20 Gy, were treated as in (B). TNF (100 ng/ml) served as positive 
control. Dendritic cells were differentiated for 5 days, and subsequently exposed to the treated 
samples for 4 h. 2 days after exposure, surface expression of CD80 was measured by flow cytometry 
and fold change was calculated as in (A). Means ± s.d. of four biological replicates are shown. 
Asterisk indicates p<0.05 as determined by unpaired Student’s t-test against 0 Gy. (E) Release of 
HSP70, HMGB1, and S100A8/A9 from irradiated HCC1937 cells. ELISAs were performed with 
supernatants of irradiated HCC1937 cells collected on day 1-4 after irradiation. Concentrations were 
calculated on the basis of standard curves. HSP70: Means ± s.d. of three biological replicates are 
shown. HMGB1: Means ± s.d. of triplicates are depicted. S100A8/A9: Means ± s.d. of five biological 
replicates are shown. Comparison of curves from irradiated samples to 0 Gy was performed by two-
way ANOVA. 
 
In the maturation approach, monocytes were differentiated to dendritic cells with GM-
CSF and IL-4 for 5 days and subsequently were treated with supernatants of 
irradiated HCC1937 cells and the respective controls (TNF or serum-free X-Vivo 15 
medium) (Figure 15C). The expression of the dendritic cell markers showed the same 
pattern as in the differentiation approach, only to lower extents, and the strongest 
effects were observed for upregulation of CD80 expression. Supernatants of 
ablatively irradiated HCC1937 cells clearly increased CD80 expression, whereas only 
moderate effects were seen for supernatants of 2 Gy and daily 2 Gy irradiated 
HCC1937 cells. Again, CD80 upregulation was predominantly mediated by proteins 
>10 kDa (Figure 15D). Overall, the influence of supernatants of irradiated HCC1937 
on monocyte differentiation was more pronounced than that on dendritic cell 
maturation. 
So far, these results show that supernatants of ablatively irradiated HCC1937 cells 
stimulate and support endothelial cell activation (Figure 14), monocyte differentiation, 
and dendritic cell maturation (Figure 15). The responsible molecular entities in this 
regard are of high molecular weight (i.e. larger than 10 kDa) and sensitive to 
proteinase digestion. Consequently, we next measured the levels of prototypical, 
proteinaceous DAMPs known to cause the observed effects in supernatants of 
irradiated HCC1937 cells (Figure 15E). HSP70, HMGB1, and the S100A8/A9 dimer 
were taken into closer consideration, since these proteinaceous DAMPs have been 
reported to be released from necrotic cells, are larger than 10 kDa (HSP70: Mw=70 
kDa, HMGB1: Mw=25 kDa, S100A8/A9 dimer: Mw=36.5 kDa), and possess 
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modulatory functions in neutrophil and monocyte attraction, endothelial cell 
activation, and dendritic cell maturation 50. Evident radiation- and time-dependent 
increases in HSP70, HMGB1, and S100A8/A9 dimer levels in the supernatants of 
irradiated HCC1937 cells were detected, clearly reflecting the profiles of endothelial 
cell activation, monocyte differentiation, and dendritic cell maturation. More precisely, 
lowest effects were observed with 0 Gy samples, increased and similar effects were 
found for 2 Gy and daily 2 Gy, and strongest effects were noticed with ablatively 
irradiated samples (Figure 14, Figure 15).  
Taken together, not only endothelial cell activation but also dendritic cell 
differentiation and maturation are supported by proteins (larger than 10 kDa) 
released from dying breast cancer cells, especially after ablative irradiation. 
Proteinaceous DAMPs, including HSP70, HMGB1, and S100A8/A9 dimer are 
potential candidates, which may mediate the observed immunological effects. 
7.9 Dendritic cell effector functions are crucially influenced by dying 
breast cancer cells 
After monocyte recruitment and dendritic cell differentiation, the induction of an 
adaptive immunity requires the (cross-) presentation of antigens by dendritic cells to 
T cells. Phagocytosis of antigen material and/or cell debris by dendritic cells is a 
prerequisite in this context.  
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Figure 16 Pivotal effector functions of dendritic cells are enhanced after contact with irradiated 
breast cancer cells. 
(A) Irradiated HCC1937 cells were subjected to phagocytosis assays using dendritic cells as 
phagocytes. Primary human monocytes were labelled with PKH67 (green), and differentiated to 
dendritic cells with GM-CSF (20 ng/ml) and IL-4 (40 ng/ml) for 5 days. Afterwards, dendritic cells 
(effector cells; E) were added to irradiated, PKH26-labeled (red) HCC1937 cells (target cells; T) on 
day 4 after irradiation at the depicted T:E ratios. Phagocytosis of irradiated HCC1937 cells by dendritic 
cells was allowed for 2 h. Subsequently, dendritic cells were analyzed by flow cytometry. Phagocytosis 
rates were calculated as the percentage of PKH67/PKH26 double-positive dendritic cells of all PKH67-
positive cells deployed. Means ± s.d. of five biological replicates are shown. Comparison of curves 
from irradiated samples to 0 Gy was performed by two-way ANOVA. (B) Active phagocytosis of 
irradiated HCC1937 cells by dendritic cells was confirmed by addition of the actin polymerization 
inhibitor cytochalasin D. Dendritic cells were incubated with 20 µM cytochalasin D for 1 h prior to the 
phagocytosis assay. Afterwards, the phagocytosis assay was performed as in (A) with a T:E ratio of 
1:4. Means ± s.d. of five biological replicates are shown. (C) Proliferation of T cells stimulated by 
allogeneic dendritic cells differentiated in the presence of tumor-derived material. Primary human 
monocytes were incubated for 4 h with supernatants of irradiated HCC1937 cells collected on day 4 
after irradiation. TNF (50 ng/ml) served as a positive control. Subsequently, monocytes were 
differentiated to dendritic cells in the presence of GM-CSF (20 ng/ml) and IL-4 (40 ng/ml). After 7 days, 
T cells from an allogeneic donor were isolated and labeled with CSFE. Dendritic cells and labeled T 
cells were cocultured at a ratio of 1:5 for 5 days. Afterwards, T cell proliferation was analyzed by flow 
cytometry. To distinguish between different subsets, T cells were stained against CD3, CD4, and CD8. 
The proliferation rate of CD4+ and CD8+ T cells was calculated as the percentage of 
CD3+CFSElowCD4+ (left panel) or CD3+CFSElowCD8+ (right panel) on the basis of all CD3+CD4+ or 
CD3+CD8+ cells, respectively, and normalized on the corresponding 0 Gy sample. Means ± s.d. of six 
biological replicates are shown. Asterisks indicate p<0.05 as determined by unpaired Student’s t-test 
against 0 Gy. 
 
The capacity of dendritic cells to phagocytose irradiated breast cancer cells in vitro 
was assessed by flow cytometry. Green PKH67-labeled dendritic cells (effector cells) 
were added to irradiated, orange PKH26-labeled HCC1937 cells (target cells) in 
increasing target to effector ratios (T:E), and internalization of dying cell material was 
quantified by flow cytometry. With increasing T:E ratios, the percentage of 
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phagocytosing dendritic cells increased. Importantly, uptake of irradiated HCC1937 
by dendritic cells was significantly higher as compared to non-irradiated control 
HCC1937 cells (Figure 16A). T cell-stimulation by dendritic cells is a key step in the 
induction of T cell-dependent adaptive immunity. Dendritic cells present and cross-
present antigens on MHC class II and I molecules to the T cell receptor. Yet, the 
interaction between the MHC complex and the T cell receptor is necessary but not 
sufficient to stimulate T cells. Co-stimulatory ligands, including CD80 and CD86 on 
the dendritic cell are needed to bind to their corresponding receptors on the T cell (in 
this case CD28) in order to fully activate the T cell. As seen before, dendritic cells, 
which had been differentiated from monocytes in the presence of supernatants of 
irradiated HCC1937 cells, expressed higher levels of co-stimulatory ligands, 
especially CD80 (Figure 15). To investigate the T cell-stimulating potential of these 
dendritic cells, an allogeneic mixed leukocyte reaction (MLR) was set up. The 
proliferation of CFSE-labeled CD4+ and CD8+ T cells was monitored as a marker for 
T cell activation (Figure 16C). Dendritic cells stimulated with TNF or X-Vivo 15 
medium served as positive or negative controls, respectively. There was a moderate 
but significant increase in CD8+ T cell proliferation when dendritic cells were 
differentiated in the presence of supernatants of ablatively irradiated HCC1937 cells 
in comparison to the non-irradiated controls. CD4+ T cell proliferation was also 
slightly increased, but this was independent of the irradiation regimen employed and 
did not reach statistical significance. 
In summary, dendritic cells efficiently phagocytose irradiated HCC1937 cells. 
Moreover, dendritic cells differentiated from monocytes in the presence of irradiated 
breast cancer supernatants induce improved CD8+ T cell proliferation. Thus, central 
steps in the induction of adaptive immunity, i.e. the recruitment of monocytic cells by 
activated endothelial cells, the differentiation and maturation of monocytes into 
dendritic cells, the phagocytosis of dying tumor cells, and the stimulation of T cell 
proliferation by these dendritic cells all were examined in the context of breast cancer 
irradiation, and the strongest effects were noticed for cancer cells subjected to 
ablative irradiation with a high single dose. 
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8 Discussion 
In the present study, the immune-stimulatory effects of ionizing irradiation were 
examined in models of breast cancer. Comparing single low dose (2 Gy), classically 
fractionated (4x2 Gy), and ablative irradiation regimens (20 Gy), we analyzed the 
quality and the extent of cell death induction in different breast cancer cell lines, the 
subsequent release of DAMPs, as well as their impact on endothelial cell activation, 
myeloid cell recruitment in vitro and in vivo, APC differentiation and maturation. 
Finally, we assessed phagocytosis of irradiated breast cancer cells by dendritic cells, 
and measured their capacity to stimulate adaptive T cell responses. Our results show 
that irradiation – particularly in the ablative setting – is a potent inducer of 
immunogenic cell death in cancer cells and stimulates the release of different DAMPs 
that have strong effects on other cells in the tumor microenvironment. As such, 
released nucleotides from dying breast cancer cells favor increased monocyte 
migration and chemokinesis. Proteinaceous DAMPs, including S100A8/A9, HMGB1, 
HSP70, and others, mediate endothelial cell activation as characterized by 
upregulated expression of adhesion molecules, and increased production and 
secretion of cytokines and chemokines. They also stimulate differentiation and 
maturation of APCs. Upon phagocytosis of breast cancer cells, which is clearly 
improved by irradiation, these APCs can potently trigger adaptive CD8+ T cell 
responses. 
8.1 Ablative irradiation as an inducer of immunogenic forms of cell 
death 
Apoptosis, necrosis, and senescence are well-known cell death modalities induced 
by ionizing radiation 9. However, they greatly differ in their immunogenic potential 
thus affecting the immunological consequences of irradiation. In this study, the 
mentioned cell death modalities were measured in different breast cancer cell lines 
after irradiation. 
MCF7 cells time-dependently underwent apoptosis especially after ablative 
irradiation, whereas only low rates of apoptosis were observed in HCC1937 and BT-
474 cells (Figure 8). Apoptosis is known as an immunogenically silent form of cell 
death: Professional phagocytes engulf apoptotic cells and produce anti-inflammatory 
cytokines, such as TGF-β and IL-10 134 75. In the context of tumor biology, recent 
studies showed that apoptotic tumor cells support tumor repopulation by release of 
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PGE2 in a caspase-3-dependent manner, and radiation-induced apoptosis was 
reported to promote tumor growth, accumulation of tumor-promoting macrophages, 
as well as angiogenesis 135 136 137. Thus, apoptosis induction in tumor cells may not 
only favor tumor repopulation but also appears to contribute to shaping an immune-
suppressive microenvironment 138. Indeed, shifting apoptosis to more immunogenic 
forms of cell death by interfering with either apoptotic cell death pathways or the 
engulfment of apoptotically dying cells, respectively, may be an interesting approach 
for the induction of anti-tumor immune mechanisms 139 140 141. 
In contrast to apoptosis, necrosis is a highly immunogenic form of cell death. Loss of 
plasma membrane integrity is a critical event in this context, because passively 
released DAMPs such as nucleotides (ATP, UTP), HMGB1, HSPs, S100A8/A9, and 
monosodium urate are main triggers for pro-inflammatory immune mechanisms 
stimulated by necrotic cells 9. 
In our experimental setting, primary necrosis was preferentially observed upon 
ablative irradiation in the fast-proliferating breast cancer cell lines HCC1937 and 
MCF7 (Figure 9). In case of fractionated and single 2 Gy radiation, the levels of 
necrosis were clearly lower. This suggests a shift from weakly to highly immunogenic 
cell death, which can be induced by ablative irradiation. Notably, this pattern seen for 
the induction of necrotic cell death – i.e. strong effects after ablative irradiation and 
less pronounced effects after fractionated or single 2 Gy radiation – recurred in nearly 
all steps of the anti-tumor immune cascade investigated in this study (see Figure 3).  
For the attraction of monocytic cells, necrotic cells appeared to be the main source of 
nucleotides, especially after ablative irradiation (Figure 10). This observation is in line 
with findings of others, who showed that intra-tumoral recruitment of monocytes was 
highly dependent on ATP released by dying cancer cells upon anthracycline 
treatment 142. Nucleotides bind to purinergic receptors such as P2RY2, thereby acting 
as ‘find-me’ signals for monocytes and macrophages 54. The important role of 
nucleotides in this scenario is indicated by the abrogation of monocyte attraction 
through the expression of the ectonucleotidase CD39. As seen in the present study, 
MCF7 cells upregulated CD39 in response to irradiation, thus completely inhibiting 
nucleotide-mediated monocyte migration (Figure 11). CD39 expression as an 
immune escape mechanism has been described for several other types of cancer, 
including melanoma, and pancreatic cancer, as well as for cancer exosomes  143 144 
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145 146 147. Moreover, degradation of ATP to adenosine by CD39, in concert with 
CD73, is a key mechanism by which regulatory T cells and MDSCs inhibit effector T 
cells to eliminate cancer cells 148 149 150.  
Despite potently stimulating monocytic cell migration in trans-well assays, 
supernatants of irradiated HCC1937 cells failed to induce directed chemotaxis of 
primary human monocytes in 2D chemotaxis assays. Instead, monocytes displayed 
undirected chemokinesis, which could be abrogated by apyrase treatment, and thus 
was mainly driven by nucleotides (Figure 12). Therefore, nucleotides per se appear 
unable to induce chemotaxis in vitro, a finding which also has been reported by 
others 130 55. This discrepancy between the in vivo observation of Ma et al. and our in 
vitro results might be resolved by recently published data from McDonald et al. They 
could show that, in the case of sterile inflammation, ATP activates P2RX7 on tissue 
macrophages, leading to the release of IL-1β, which in turn activates endothelial cells 
thereby supporting neutrophil extravasation 52. Hence, nucleotides alone may act as 
amplifiers through indirect activation of endothelial cells but not as direct stimulators 
of leukocyte recruitment. 
In addition to nucleotides, high levels of the prototypical DAMPs HSP70, HMGB1 and 
S100A8/A9 were detected in the supernatants of irradiated HCC1937 cells 
particularly after ablative irradiation (Figure 15). The role of these DAMPs as pro-
inflammatory mediators will be discussed in greater detail in chapter 8.5. However, it 
should be highlighted at this point that release of these DAMPs greatly contributes to 
the immunogenic potential of irradiation-induced cell death, especially in terms of 
endothelial cell activation and APC differentiation. Therefore, the quality of cell death 
induced by ablative irradiation, i.e. high levels of primary necrosis combined with the 
release of highly immunogenic DAMPs, indicates that ablative irradiation potently 
stimulates immunogenic forms of cell death. 
Besides necrosis, necroptosis was described as another form of immunogenic cell 
death 151. In the present study, only a marginal contribution of necroptosis upon 
irradiation could be detected by using the necroptosis inhibitor necrostatin-1 (Figure 
8). The role of autophagy in cancer suppression/promotion is still discussed 
controversially and was not addressed in this study 152. However, especially 
autophagy-induced release of nucleotides was shown to contribute to immunogenic 
effects of radiation and might thus be of interest for future studies 153. 
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Lastly, the induction of senescence upon irradiation was analyzed. Senescence is 
characterized by irreversible cell cycle arrest while senescent cells in principle 
maintain metabolic activity 77. The immunogenic potential of senescent cells is 
described ambiguously in the literature. Senescent cells are known to secrete various 
cytokines, chemokines, and growth factors summarized as the senescence-
associated secretory phenotype (SASP). The SASP exerts both immune-stimulating 
as well as immune-suppressive functions. For instance, secretion of various 
chemokines from senescent cancer cells was reported to mediate NK cell-dependent 
elimination of liver carcinoma cells 154. However, continuous release of cytokines 
from senescent cells appears to switch the nature of tumor-infiltrating leukocyte 
subpopulations from an anti- to a pro-tumorigenic one 78. Further studies should 
characterize the SASP of irradiation-induced senescent breast cancer cells in order 
to dissect their contribution to anti-tumor immune mechanism in greater depth. 
8.2 Endothelial cells as potential organizers of myeloid cell recruitment 
to dying cancer cells upon ablative radiotherapy 
Endothelial cells are of crucial importance for leukocyte recruitment during 
inflammation 81. In principal, endothelial cells exhibit two essential functions: First, 
they release cytokines and chemokines for leukocyte attraction, and second, they 
express adhesion molecules on their surface for leukocyte extravasation. Both 
functions were analyzed in this study in order to assess whether endothelial cells are 
able to convert the observed chemokinetic migration of monocytic cells to 
supernatants of irradiated HCC1937 cells in vitro (Figure 12) into directed migration 
in vivo.  
Incubation of HUVECs with cell-free supernatants of ablatively irradiated HCC1937 
cells resulted in a strong upregulation of the adhesion molecules ICAM-1, VCAM-1, 
and E-selectin necessary for leukocyte-endothelial cell adhesion. This upregulation 
was less pronounced with supernatants of single 2 Gy or fractionatedly irradiated 
HCC1937 cells. ICAM-1 surface expression on HUVECs was dependent on proteins 
released from irradiated HCC1937 cells suggesting that proteinaceous DAMPs, such 
as HMGB-1, HSP70, S100A8/A9, and others, are involved (Figure 15). Indeed, 
HUVECs express several pattern recognition receptors for DAMPs, such as TLR4 
and RAGE, which may render them susceptible to HMGB1, HSP70, and S100A8/A9 
155 69 156. E-selectin is known to mediate capture and especially rolling of leukocytes 
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by interacting with PSGL1 and CD44, while ICAM-1 and VCAM-1 mediate leukocyte 
arrest and crawling on the endothelial cells by interacting with integrins 81.  P-selectin, 
which exerts similar functions as E-selectin during capture and rolling of leukocytes, 
could not be detected on HUVECs (data not shown). Since P-selectin expression in 
HUVECs is highly dependent on the culture conditions, this might explain its absence 
in our setting. The functional validation of adhesion molecule upregulation on 
HUVECs after exposure to cell-free supernatants of irradiated HCC1937 cells is 
currently under investigation with primary human neutrophils and monocytes in flow 
chamber assays in cooperation with Prof. Markus Sperandio from the Walter Brendel 
Centre of Experimental Medicine, Klinikum der Universität München, Munich, 
Germany. 
In addition to adhesion molecule surface expression, supernatants of irradiated 
HCC1937 cells induced the production of various cytokines and chemokines in 
HUVECs (Figure 14). Upon incubation with supernatants of ablatively irradiated 
HCC1937 cells, HUVECs upregulated a unique cytokine mRNA profile. IL-6, MIP-2a, 
CXCL1, MCP-3, and MIP-2b were observed as the strongest determinants in this 
context. This cytokine profile was clearly different from the ones stimulated by 
supernatants of the other irradiation regimens and that of the positive control TNF, 
suggesting that HUVECs are strongly activated by supernatants of ablatively 
irradiated HCC1937 cells, but obviously distinct from TNF-dependent activation (as 
for instance during pathogen-associated inflammation). Of note, the mentioned 
cytokines IL-6, MIP-2a, CXCL1, MCP-3, and MIP-2b were also found at high 
concentrations in HUVEC supernatants after incubation with supernatants of 
ablatively irradiated HCC1937 cells. Additionally, IL-8, MIF, MCP-1, and IL-1β were 
secreted although the effects on mRNA levels were rather modest. The importance of 
these cytokines/chemokines for immune responses has been demonstrated in 
numerous studies, especially in the context of sterile inflammation and anti-tumor 
immunity. IL-6 has local and systemic functions during inflammation: Production and 
release of acute-phase proteins from the liver and the induction of fever rely strongly 
on IL-6. Locally, IL-6 promotes differentiation of naïve CD4+ and CD8+ T cells into T 
helper cells and cytotoxic T cells, respectively, and simultaneously suppresses 
regulatory T cells 157 158. Both MCP-1 and MCP-3 were shown to be important for 
intra-tumoral recruitment of leukocytes. In anthracycline-treated mouse 
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fibrosarcomas, MCP-1 was shown to be essential for the intra-tumoral recruitment of 
highly competent APCs 133, and MCP-3 delivery in murine mastocytoma facilitated 
dendritic cell-dependent tumor rejection by lymphocytes 159. IL-1β, which has been 
reported to be produced by resident macrophages upon exposure to nucleotides 
released during sterile inflammation 160, can promote the upregulation of ICAM-1 on 
and the release of CXCL1 and MIP2a from endothelial cells, resulting in neutrophil 
recruitment to sites of sterile inflammation 52. Hence, a pro-inflammatory milieu is 
generated by HUVECs after incubation with supernatants of irradiated cells via 
release of systemically and locally effective cytokines and chemokines. This effect 
was most apparent with ablatively irradiated HCC1937 cells. Recently, Stark and 
colleagues demonstrated that pericytes release a panel of cytokines and chemokines 
which attract neutrophils and monocytes in the context of sterile inflammation. 
Notably, this panel consisted of IL-6, CXCL1, IL-8, MIF, MCP-1 and IL-1β 97, showing 
a striking degree of overlap to the panel observed in the present study. Our results 
from the air pouch model further underline the parallels between myeloid cell 
recruitment in the context of cancer radiotherapy and sterile inflammation: 
Predominantly neutrophils as well as monocytes were time-dependently recruited into 
the pouches after injection of supernatants of irradiated HCC1937 cells. Notably, the 
sequence of leukocyte infiltration, i.e. initially neutrophils, followed by monocytes in a 
second wave, reflected the neutrophil-monocyte axis postulated for inflammation 161. 
Interestingly, besides neutrophils, the number of Ly6Clow monocytes was significantly 
higher in pouches containing supernatants of ablatively irradiated HCC1937 cells as 
compared to those injected with supernatants of single 2 Gy or fractionatedly 
irradiated HCC1937 cells. In contrast, no significant differences between 
supernatants of ablatively and fractionatedly irradiated HCC1937 cells were seen for 
the numbers of infiltrating Ly6Chi monocytes. These inflammatory monocytes are 
rapidly recruited from the blood to sites of inflammation were they differentiate into 
inflammatory dendritic cells 162. During differentiation, Ly6C surface expression 
decreases, thereby giving rise to Ly6Clow monocytic cells. Tissue-resident monocytes 
and monocyte-derived cells, such as Langerhans cells, also are Ly6Clow 163 164. Thus, 
supernatants of fractionatedly and ablatively irradiated HCC1937 cells might induce 
inflammatory monocyte recruitment to a similar extent, but either maturation and/or 
loss of Ly6C expression are accelerated in case of supernatants of ablatively 
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irradiated HCC1937 cells, or infiltration of tissue-resident monocytes/monocytic cells 
is elevated, respectively. In some studies, the infiltrating T cell-stimulating APC-
subpopulation in the context of tumor therapy was described as Ly6Chi 132 133. 
Therefore, it will be of relevant interest for future studies to analyze the phenotypes of 
monocyte-derived cells emerging from infiltrating monocytic subsets in further detail. 
8.3 Dying cancer cell material stimulates the differentiation of dendritic 
cells to potent APCs 
Dendritic cells are the most important APCs interacting with naїve T cells. The origin 
of (cross-) presented antigens, the expression of co-stimulatory receptors and the 
cytokine profile of mature dendritic cells determine whether naїve T cells become 
effector or tolerogenic T cells. Therefore, the phenotype of dendritic cells is crucial for 
the induction of adaptive immunity. Two scenarios of dendritic cell 
differentiation/maturation were investigated in this study: (i) dendritic cells that were 
differentiated from monocytes in the presence of cell culture supernatants of 
irradiated HCC1937 tumor cells, and (ii) dendritic cells that were exposed to culture 
supernatants of irradiated HCC1937 tumor cells after differentiation. These 
approaches were chosen to determine the effects of dying cancer cell-derived factors 
(i) on peripheral blood monocytes, which are newly recruited to the site of irradiation-
induced tumor cell death, thereby undergoing differentiation to dendritic cells in the 
environment of the irradiated tumor (‘new’ dendritic cells), and (ii) on tissue-resident 
dendritic cells reacting to tumor cell death (‘resident’ dendritic cells).   
Commonly, intra-tumoral dendritic cells are often described to have an immune-
suppressive phenotype 165. They are poorly differentiated, express only low levels of 
co-stimulatory molecules, and release anti-inflammatory cytokines, such as IL-10 and 
IL-13, leading to anergy of CTLs, immune tolerance, promotion of tumor growth, and 
metastasis 166 167. Recently, Broz et al. detected an intra-tumoral subpopulation of 
dendritic cells, which turned out to be highly potent APCs. However, this dendritic cell 
phenotype was rarely found in established mouse mammary carcinomas in 
comparison to MDSCs – a finding, which relativizes the immunogenic potential of 
these dendritic cells 168 169. Yet, the immune-suppressive effect of intra-tumoral 
MDSCs may be overcome by freshly recruited myeloid-derived dendritic cells. For 
anthracycline therapy it was shown that monocytes of CD11c+CD11b+Ly6Chi 
phenotype can differentiate into potent CD86+ dendritic cells after intra-tumoral 
92 
 
recruitment and induce potent anti-tumor immunity 132. In accordance, emergence of 
an immune-stimulatory APC-phenotype in the presence of dying cancer cell-derived 
factors is suggested in the present study by the strong upregulation of CD80 on ‘new’ 
dendritic cells – particularly with supernatants of ablatively irradiated HCC1937 cells. 
Supernatants of single 2 Gy and fractionatedly irradiated HCC1937 cells also induced 
CD80 upregulation, but to a much lesser extent. Regarding the responsible molecular 
entities within the culture supernatants, the same pattern was seen as in the HUVEC 
activation experiments: Both the endothelial cells’ response and the induction of co-
stimulatory CD80 on dendritic cells were dependent on proteins of >10 kDa released 
from irradiated HCC1937 cells, suggesting the involvement of similar signals, 
presumably proteinaceous DAMPs, such as HMGB1, HSP70, and S100A8/A9 
(Figure 15). In terms of the different irradiation regimens, the expression pattern of 
CD80 on ‘resident’ and ‘new’ dendritic cells was similar – i.e. supernatants of 2 Gy 
and fractionated irradiated cells stimulated CD80 upregulation less potently than 
those of ablatively irradiated cells did. However, the magnitude of induction was 
higher on ‘new’ dendritic cells. Since CD86 functions as a co-stimulator for T cells 
analogously to CD80, it might me dispensable. CD40 is a co-stimulatory receptor for 
dendritic cells, which is bound by CD40L on T cells, thereby activating the dendritic 
cells. It is known to be involved in upregulation of CD80 and CD86 170. Although 
supernatants of irradiated HCC1937 cells increased CD40 expression on dendritic 
cells only moderately, CD80 was robustly upregulated, indicating either a strong 
amplification cascade or a minor role for CD40 in this setting, respectively. Antigens 
presented on MHC class II molecules, such as HLA-DR, are recognized by CD4+ T 
cells. Expression of HLA-DR on ‘new’ and ‘resident’ dendritic cells was only slightly 
altered upon exposure to supernatants of irradiated HCC1937 cells. However, in both 
cell populations basal HLA-DR expression levels were very high (data not shown) 
suggesting that these levels can only be further increased by very strong signals, as 
the positive control TNF. In addition to the analyzed surface receptors and co-
stimulatory molecules, CCR7, the lymph node homing receptor for dendritic cells, is 
an important player in dendritic cell maturation, and has not been addressed in the 
present study 104. Since (cross-) presentation of antigens by dendritic cells to T cells 
takes place in the lymph node, CCR7 expression should be investigated in further 
studies.  
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Another interesting issue, which should be addressed in the future, is the cytokine 
panel released from ‘new’ or ‘resident’ dendritic cells, respectively. T cell (cross-) 
priming by dendritic cells is dependent on three events, as mentioned earlier: (i) 
antigen (cross-) presentation on MHC molecules, (ii) co-stimulation by binding of 
CD80/CD86 to CD28, and (iii) release of distinct T cell-activating cytokines, such as 
IL-2, by dendritic cells. The capacity of different dendritic cell populations to release 
such cytokines and, especially, type I IFNs in the context of tumor radiotherapy 
should therefore be investigated in the future. 
8.4 Dendritic cells connect innate and adaptive immune mechanisms in 
the context of anti-tumor immunity 
Dendritic cells represent a crucial link between the innate and adaptive immune 
system, which is mirrored in their ability to phagocytose cell debris and (cross-) 
present the processed material to T cells. Their ‘innate function’, i.e. the engulfment 
of cell debris for antigen (cross-) presentation, was measured in phagocytosis 
assays. Irradiated HCC1937 cells were efficiently engulfed by dendritic cells. Notably, 
dendritic cells phagocytosed ablatively and fractionatedly irradiated HCC1937 cells to 
comparable extents, suggesting that from an efferocytic point of view, these prey cell 
populations look identical. Only cells subjected to the single low dose setting and 
viable control cells were clearly less engulfed.  
HCC1937 cells primarily underwent primary necrosis after irradiation, but apoptosis 
and senescence were also induced, especially after ablative irradiation (see Figure 
9). Since the (post-) phagocytic response is influenced by the cell death properties, it 
is important to discuss the observed cell death modalities in HCC1937 cells in the 
context of phagocytosis. 
Exposure of phosphatidylserine (PS) is the main trigger for phagocytosis of apoptotic 
cells 171. During apoptosis, PS translocates from the inner to the outer plasma 
membrane leaflet 172 173. PS binds either directly to specific receptors such as BAI-1 
174 and TIM-1,-4 175 or indirectly via bridging proteins including MFG-E8 and Del-1, to 
αvβ3/5 integrins 176, leading to re-arrangements in the phagocyte’s actin skeleton and 
finally to cell engulfment. However, as described before, HCC1937 cells 
predominantly underwent primary necrosis after irradiation. The engulfment of 
necrotic cells is less well understood, but rupture of the plasma membrane during 
(primary and secondary) necrosis also results in PS exposure. Therefore, PS-
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dependent phagocytosis may also account for necrotic cell engulfment, however to a 
lesser extent 177. To be more precise, oxidized PS in conjunction with non-oxidized 
PS has been described as a strong signal for phagocytosis of dying cells 178. Since 
ionizing radiation induces the formation of reactive oxygen species, this might explain 
the difference between the uptake of fractionatedly and single 2 Gy irradiated 
HCC1937 cells: Cell death induction was found to be in the same range for both 
radiation regimens but daily doses of 2 Gy might lead to more oxidation of PS, and 
thus facilitate tumor cell engulfment.  
The post-phagocytic response differs fundamentally between apoptotic and necrotic 
cells: As mentioned before, upon uptake of apoptotic cells, macrophages release 
immune-suppressive cytokines and dendritic cells induce immune-tolerance in T cells 
179, while internalization of necrotic cells induces pro-inflammatory reactions of 
macrophages and dendritic cells, such as pro-inflammatory cytokine release and T 
cell priming. Therefore, the post-phagocytic response of dendritic cells after 
engulfment of irradiated HCC1937 cells might be of interest for further studies. 
The clearance of senescent cells is only poorly understood. In murine liver 
carcinomas, p53-dependent senescent tumor cells were cleared by cells of the innate 
immune system 180. However, the exact mechanisms, the involved signals, and 
receptors still remain elusive 9. 
Finally, it should be noted that the phagocytosis assay was performed as a co-culture 
experiment, i.e. dendritic cells and irradiated HCC1937 cells were in direct contact. 
Therefore, effects induced by irradiated HCC1937 might be over-estimated in this 
assay in comparison to assays where dendritic cells/monocytes were stimulated with 
supernatants of irradiated HCC1937 cells. Moreover, it is noteworthy that dendritic 
cells and HCC1937 cells were obtained from different donors (allogeneic system), 
which most likely enhances the phagocytic activity of dendritic cells in comparison to 
an autologous situation where both dendritic cells and tumor cells are derived from 
the same individual. 
Following ingestion of cell debris, dendritic cells process the engulfed material and 
(cross-) present antigens derived thereof on MHC molecules to T cells, thus 
stimulating adaptive immune responses. Investigating this ‘adaptive function’ of 
dendritic cells, the ability of dendritic cells to stimulate T cell proliferation was 
monitored in this study by allogeneic mixed leukocyte reactions (Figure 16). Dendritic 
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cells, which were differentiated in the presence of supernatants of ablatively or 
fractionatedly irradiated HCC1937 cells, induced CD8+ T cell proliferation significantly 
stronger than the controls which were differentiated upon exposure to supernatants 
of not irradiated cells. In contrast, CD4+ T cell proliferation was only slightly but not 
significantly increased. This suggests that dendritic cells differentiated from 
monocytes in the presence of supernatants of irradiated HCC1937 cells show a 
‘cross-presenting’ rather than a ‘presenting’ phenotype (i.e. stimulation of CD8+ T 
cells rather than CD4+ T cells). Our results from the differentiation experiments, 
where the expression of CD4-binding HLA-DR was found to be independent of the 
irradiation regimen employed for the HCC1937 cell supernatants, further support this 
conclusion. In contrast, the co-stimulatory receptor CD80 was strongly upregulated 
upon exposure to supernatants of ablatively irradiated HCC1937 cells. Therefore, the 
surface receptor expression status of ‘new’ dendritic cells which have been 
differentiated in the presence of factors released from ablatively irradiated HCC1937 
cells and their functional performance suggest a more CD8+ T cell stimulatory 
phenotype. 
Previously, it has been shown that both local and systemic anti-tumor immunity 
induced by radiotherapy strongly rely on cytotoxic CD8+ T cells 13, while CD4+ T cells 
seem to be dispensable 22. Cytotoxic CD8+ T cells directly kill infected or malignant 
cells, which present foreign or abnormal antigens on MHC class I molecules. CD4+ T 
cells consist of different subpopulations such as T helper cells or immunosuppressive 
regulatory T cell subsets, and are unable to kill cells directly. The CD4+ T cell 
subpopulations differ in their cytokine repertoire, resulting in either immune-
suppressive or immune-promoting functions. CD4+ regulatory T cells inhibit cytotoxic 
CD8+ T cells and are often found in the immunosuppressive microenvironment in 
different cancer types (e.g. breast cancer, non-small cell lung cancer, and pancreatic 
adenocarcinoma 181 182 183). It could be shown that the anti-tumor immune response 
is enhanced when CD4+ T cells were eliminated 23. Therefore, enhancing CD8+ T cell 
proliferation and, concurrently, preventing CD4+ T cell proliferation may be favorable 
for a profound anti-tumor response. However, upon virus infections, it is well-known 
that CD4+ T cells are indispensable to maintain cytotoxic CD8+ T cell function 184. 
Furthermore, effector memory CD4+ T cells were found in the blood of metastatic 
melanoma or renal cell carcinoma patients who showed abscopal, systemic immune 
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effects after stereotactic body radiotherapy plus IL-2 treatment 185. Thus, for direct 
anti-tumor effects CD4+ T cells might be dispensable but for long-lasting CD8+ T cell-
dependent tumor control, CD4+ T cells appear to be required 14. In the present study, 
tumor cell killing properties such as FasL upregulation, granzyme B and IFNγ 
production of activated CD8+ T cells were not investigated. This issue should be 
addressed in further studies to confirm the anti-tumor effectiveness of CD8+ T cells. 
Additionally, the relevance of different CD4+ T cell subsets needs to be clarified in 
greater detail. 
8.5 DAMPs as potential mediators of tumor immunogenicity stimulated 
by ablative irradiation 
DAMP release is a key feature of immunogenic cell death 186. As mentioned before, 
irradiation induced the liberation of nucleotides from necrotic breast cancer cells. 
Moreover, proteins derived from irradiated HCC1937 cells stimulated endothelial cell 
activation and dendritic cell differentiation in the described, recurring pattern: 
Strongest effects with supernatants of ablatively irradiated HCC1937 cells and lower, 
but similar effects for fractionatedly and single 2 Gy irradiated HCC1937 cells. In the 
present study, the proteinaceous DAMPs HSP70, HMGB1, and S100A8/A9, which 
are known to passively leak out during necrosis 50, were detected at high 
concentrations in the supernatants of irradiated HCC1937 cells. Notably, all of them 
were found to be released in a time-dependent manner reflecting the observed 
pattern of HUVEC activation and dendritic cell differentiation. S100A8/A9 release 
reflected this pattern best: The highest concentrations were observed in supernatants 
of ablatively irradiated HCC1937 cells, slightly less for 4x2 Gy and 1x2 Gy, and the 
lowest concentration was found in the not irradiated controls. Notably, the 
S100A8/A9 heterodimer, besides other S100 proteins, was found to be 
overexpressed in breast cancer 187. Recent data support the ability of S100A8/A9 to 
activate endothelial cells as well as monocytes 188 69. S100A8/A9 was reported to 
induce an inflammatory phenotype in human microvascular endothelial cells, leading 
to the upregulation of pro-inflammatory chemokines such as IL-8 and CXCL1, and 
adhesion molecules such as ICAM-1 and VCAM-1 188. It was found that S100A8/A9 
activates monocytes by binding to TLR4, thereby enhancing the expression of pro-
inflammatory TNF 69. Interestingly, HMGB1 is also known to exert its immune-
supporting effects by binding to TLR4, and the same is true for HSP70 62 156. 
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Furthermore, slow rolling and adhesion of neutrophils seem to be controlled by 
S100A8/A9, resulting in increased neutrophil recruitment 189. Therefore, S100A8/A9 
may act as a strong immune-promoting DAMP. Nevertheless, immune-suppressive 
functions of S100A8/A9 are also found in the literature. MDSCs may be attracted by 
S100A8/A9 in a paracrine and autocrine fashion 190. Furthermore, breast cancer 
metastasis into the lung was shown to be promoted by S100A8/A9 191.  
However, in the present study, the suggested contribution of S100A8/A9 to the 
observed effects on endothelial cell activation (see chapter 7.7) and dendritic cell 
differentiation (see chapter 7.8) seems to be of immune-supporting character. 
Presumably, HMGB1 and HSP70 may also be of importance for inducing the 
described effects, since both are well-established pro-inflammatory DAMPs 57 60, 
which can be found at high levels in tumor cell supernatants after irradiation. 
Depleting these DAMPs or inhibiting their functions might help to dissect their 
individual contribution to the observed immune-stimulatory effects in the future. In 
summary, ablative irradiation is a strong inductor of DAMP release, strengthening the 
role of irradiation-induced necrosis as a form of immunogenic cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
98 
 
9 Conclusions 
The aim of the present study was to elucidate the differences between fractionated 
and ablative irradiation with regard to their immune-stimulatory effects in models of 
breast cancer. It could be shown that ablative irradiation induces an immunogenic, 
necrotic form of cell death especially in fast-proliferating, triple-negative breast cancer 
cells, thereby instigating different immune-stimulatory mechanisms: DAMPs released 
from necrotic breast cancer cells activated endothelial cells in vitro which resulted in 
the recruitment of myeloid cells in vivo. Dendritic cells did not only phagocytose dying 
tumor cells but also revealed enforced maturation upon exposure to necrotic cancer 
cell-derived material followed by improved stimulation of CD8+ T cells. Thus, several 
key features of systemic anti-tumor immunity apparently can be induced by ionizing 
irradiation, and the magnitude of these effects was consistently greater in case of the 
ablative irradiation regimen with 1 x 20 Gy as compared to classical fractionation with 
daily 2 Gy. The validation of these immune-stimulatory mechanisms in an orthotopic, 
syngeneic mouse breast cancer model will be essential in order to gain deeper 
insights into their translational relevance. This is of crucial importance for a central 
question that arises from the present work: How can these systemic immune-
stimulatory observations be transferred into therapeutic concepts? Some ideas 
should be taken into consideration: IORT with ablative irradiation doses is commonly 
applied to elderly patients with reduced mobility and/or impaired health status, to 
spare them the long treatment time of fractionated radiotherapy. In this patient 
subset, the most prevalent breast cancer phenotype is the hormone-receptor 
positive, slow-proliferating one with good prognosis. However, the present study 
demonstrates that particularly the aggressive, fast-proliferating triple-negative breast 
cancer subtype, which is mainly observed in younger women, is capable of inducing 
anti-tumor immune mechanisms upon ablative irradiation. Accordingly, IORT might 
represent a promising additional treatment option for younger patients with triple-
negative breast cancer. Furthermore, most breast cancer patients receive 
radiotherapy in adjuvant settings, i.e. after tumor resection, and therefore the amount 
of tumor cell-derived, immune-stimulatory signals that can be generated during 
radiotherapy might be insufficient to induce systemic immunity. In consequence, 
neoadjuvant irradiation settings, i.e. irradiation before tumor resection, appear worth 
to be discussed in order to support the induction of anti-tumor immunity with relevant 
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amounts of tumor antigen. Finally, the role of the tumor-draining lymph nodes in 
breast cancer therapy needs to be reevaluated. Undoubtedly, they are crucially 
involved in metastasis formation, and their surgical removal can contribute to long-
term tumor control. Nevertheless, (cross-) priming of T cells by dendritic cells – a key 
process in the induction of adaptive immunity – occurs in the draining lymph nodes. 
Hence, it is worth contemplating to adapt the treatment sequence, and – if possible – 
to allow T cell (cross-) priming prior to lymph node dissection. 
In summary, the present study confirms that diverse immune mechanisms can be 
stimulated by radiotherapy, and future research might help to translate these findings 
into optimized clinical concepts for breast cancer treatment. 
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